Substances that are recognized by the immune system and induce an immune reaction.
Substances elaborated by bacteria that have antigenic activity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Substances elaborated by viruses that have antigenic activity.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Substances of fungal origin that have antigenic activity.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
The major group of transplantation antigens in the mouse.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.
Neoplasms containing cyst-like formations or producing mucin or serum.
Antibodies produced by a single clone of cells.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Tumors or cancer of the SKIN.
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
Sites on an antigen that interact with specific antibodies.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Tumors or cancers of the KIDNEY.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the LUNG.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
Tumors or cancer of the THYROID GLAND.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the LIVER.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.
Established cell cultures that have the potential to propagate indefinitely.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A general term for various neoplastic diseases of the lymphoid tissue.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Tumors or cancer of the PAROTID GLAND.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the COLON.
Tumors or cancer of the ENDOCRINE GLANDS.
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Tumors or cancer of the EYE.
An encapsulated lymphatic organ through which venous blood filters.
Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the NOSE.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Tumors or cancer of the SALIVARY GLANDS.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
A benign epithelial tumor with a glandular organization.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Tumors or cancer of the PROSTATE.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Tumors or cancer of the UTERUS.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Tumors or cancer of the INTESTINES.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Tumors or cancer of the THYMUS GLAND.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Tumors or cancer located in bone tissue or specific BONES.
The sum of the weight of all the atoms in a molecule.
A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.
A malignant epithelial tumor with a glandular organization.
A glycolipid, cross-species antigen that induces production of antisheep hemolysin. It is present on the tissue cells of many species but absent in humans. It is found in many infectious agents.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A species of POLYOMAVIRUS originally isolated from Rhesus monkey kidney tissue. It produces malignancy in human and newborn hamster kidney cell cultures.
A sex-specific cell surface antigen produced by the sex-determining gene of the Y chromosome in mammals. It causes syngeneic grafts from males to females to be rejected and interacts with somatic elements of the embryologic undifferentiated gonad to produce testicular organogenesis.
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Elements of limited time intervals, contributing to particular results or situations.
Tumors or cancer of the SPLEEN.
Tumors or cancer of the BILE DUCTS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Neoplasms composed of more than one type of neoplastic tissue.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Tumors or cancer of the MANDIBLE.
Proteins prepared by recombinant DNA technology.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Cancer or tumors of the MAXILLA or upper jaw.
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Tumors or cancer of the STOMACH.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
Diagnostic procedures involving immunoglobulin reactions.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the anal gland.
Tumors or cancer of the human BREAST.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Immunoglobulins produced in a response to HELMINTH ANTIGENS.
Tumors or cancer of the URINARY BLADDER.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Tumors or cancer of the MOUTH.
Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.

Glycopeptides from the surgace of human neuroblastoma cells. (1/9302)

Glycopeptides suggesting a complex oligosaccharide composition are present on the surface of cells from human neuroblastoma tumors and several cell lines derived from the tumors. The glycopeptides, labeled with radioactive L-fucose, were removed from the cell surface with trypsin, digested with Pronase, and examined by chromatography on Sephadex G-50. Human skin fibroblasts, brain cells, and a fibroblast line derived from neuroblastoma tumor tissue show less complex glycopeptides. Although some differences exist between the cell lines and the primary tumor cells, the similarities between these human tumors and animal tumors examined previously are striking.  (+info)

Immune responses to all ErbB family receptors detectable in serum of cancer patients. (2/9302)

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.  (+info)

The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy. (3/9302)

AIM: To investigate the expression of CD44 isoforms containing variant exon 6 (v6) in a well characterised cohort of patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), and to correlate this with phenotype and disease course. METHODS: Cryostat sections of OCT embedded diagnostic nodal material from NHL patients and cryopreserved mononuclear preparations from CLL patients were used as sources of RNA. After reverse transcription, PCR was carried out with amplimers positioned at either side of the variant exon insertion site to amplify all possible CD44 isoforms. Those isoforms containing v6 were identified after Southern blotting and hybridisation with a radiolabelled oligonucleotide. RESULTS: Of 32 NHL samples analysed, 16 did not express CD44 isoforms containing v6, six expressed an isoform containing exon v6 alone, and 10 expressed v6 long isoforms which contained exon v6 in addition to other variant exons. These data did not correlate with lymphoma classification, disease staging, or the presence or absence of extranodal disease. However, those patients expressing v6 long CD44 isoforms had a worse overall survival than those that did not. The plateau of the survival curves was 50% compared with 82%. No v6 long isoforms were detected in the 21 CLL samples investigated. CONCLUSIONS: The expression of v6 long CD44 isoforms is associated with aggressive disease in NHL, independent of grade, stage, or presence of extranodal disease.  (+info)

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. (4/9302)

Transforming growth factor beta (TGF beta) family members are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from the N-terminal region of the TGF beta gene product. Extracellular activation of these complexes is a critical but incompletely understood step in regulation of TGF beta function in vivo. We show that TGF beta 1 LAP is a ligand for the integrin alpha v beta 6 and that alpha v beta 6-expressing cells induce spatially restricted activation of TGF beta 1. This finding explains why mice lacking this integrin develop exaggerated inflammation and, as we show, are protected from pulmonary fibrosis. These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin.  (+info)

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. (5/9302)

Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of the bladder. Using a murine bladder tumor (MB49), which we show to express the male transplantation antigen (HY), we tested the hypothesis that IL-10 at the tumor site can block the generation of a tumor-specific type 1 immune response. We show that, despite its expression of HY, MB49 fails to prime for an HY-specific type 1 (IFN-gamma) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding beta-galactosidase (beta-gal) is injected into the tumors of normal mice, no beta-gal-specific IFN-gamma response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong beta-gal-specific, IFN-gamma response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site.  (+info)

Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. (6/9302)

Dendritic cells (DC) are critically involved in the initiation of primary immune processes, including tumor rejection. In our study, we investigated the effect of interleukin-10 (IL-10)-treated human DC on the properties of CD8(+) T cells that are known to be essential for the destruction of tumor cells. We show that IL-10-pretreatment of DC not only reduces their allostimulatory capacity, but also induces a state of alloantigen-specific anergy in both primed and naive (CD45RA+) CD8(+) T cells. To investigate the influence of IL-10-treated DC on melanoma-associated antigen-specific T cells, we generated a tyrosinase-specific CD8(+) T-cell line by several rounds of stimulation with the specific antigen. After coculture with IL-10-treated DC, restimulation of the T-cell line with untreated, antigen-pulsed DC demonstrated peptide-specific anergy in the tyrosinase-specific T cells. Addition of IL-2 to the anergic T cells reversed the state of both alloantigen- or peptide-specific anergy. In contrast to optimally stimulated CD8(+) T cells, anergic tyrosinase-specific CD8(+) T cells, after coculture with peptide-pulsed IL-10-treated DC, failed to lyse an HLA-A2-positive and tyrosinase-expressing melanoma cell line. Thus, our data demonstrate that IL-10-treated DC induce an antigen-specific anergy in cytotoxic CD8(+) T cells, a process that might be a mechanism of tumors to inhibit immune surveillance by converting DC into tolerogenic antigen-presenting cells.  (+info)

Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. (7/9302)

BACKGROUND: Proper treatment of lymph node-negative breast cancer depends on an accurate prognosis. To improve prognostic models for this disease, we evaluated whether an immunohistochemical marker for proliferating cells, Ki-S2 (a monoclonal antibody that binds to a 100-kd nuclear protein expressed in S, G2, and M phases of the cell cycle), is an accurate indicator of prognosis. METHODS: We studied 371 Swedish women with lymph node-negative breast cancer; the median follow-up time was 95 months. The fraction of tumor cells in S phase was assessed by flow cytometry, and tumor cell proliferation was measured immunohistochemically with the monoclonal antibodies Ki-S2 and Ki-S5 (directed against the nuclear antigen Ki-67). A combined prognostic index was calculated on the basis of the S-phase fraction, progesterone receptor content, and tumor size. RESULTS: In multivariate analyses that did or did not (263 and 332 observations, respectively) include the S-phase fraction and the combined prognostic index, the Ki-S2 labeling index (percentage of antibody-stained tumor cell nuclei) emerged as the most statistically significant predictor of overall survival, disease-specific survival, and disease-free survival (all two-sided P<.0001). In the risk group defined by a Ki-S2 labeling index of 10% or less, life expectancy was not statistically significantly different from that of age-matched women without breast cancer, whereas the group with a high Ki-S2 labeling index had an increased risk of mortality of up to 20-fold. CONCLUSIONS: Cellular proliferation is a major determinant of the biologic behavior of breast cancer. Prognosis is apparently best indicated by the percentage of cells in S through M phases of the cell cycle. Measurement of the Ki-S2 labeling index of a tumor sample may improve a clinician's ability to make an accurate prognosis and to identify patients with a low risk of recurrence who may not need adjuvant therapy.  (+info)

Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. (8/9302)

The mRNA expression of the tumor-associated antigens MAGE and GAGE was examined in 60 high-grade brain tumors. This analysis was performed by using reverse transcription-PCR, Southern blotting, and sequencing. It was demonstrated that, of the eight GAGE genes, GAGE-2 and -7 were expressed in five of seven normal brains. Four groups of tumors--adult glioblastoma multiforme (n = 20), pediatric glioblastoma multiforme (n = 9), medulloblastomas (n = 15), and ependymomas (n = 14)--were analyzed for mRNA expression. The following frequencies were observed: MAGE-1, 0, 0, 13, and 0%, respectively; MAGE-2, 5, 11, 60, and 57%; MAGE-3 & -6, 0, 0, 13, and 0%; GAGE-1, 65, 11, 13, and 43%; and GAGE-3-6 and -8: 75, 78, 47, and 93%, respectively. Two unclassified tumors expressed GAGE-3-6 and -8 only. The absence of GAGE-1 expression in normal brain, its relatively high frequency of expression in high-grade brain tumors, and its unique 3' sequence, suggest it may represent a useful target for specific immunotherapy. The detection method of reverse transcription-PCR and Southern blotting may also be useful for rapid screening of biopsy specimens both for diagnostic purposes and to determine a patient's eligibility for specific immunotherapy.  (+info)

In several human malignancies, the expression of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is associated with aggressive characteristics and poor overall survival. RCAS1 alters the tumor microenvironment by inducing peripheral lymphocyte apoptosis and angiogenesis, while reducing the vimentin-positive cell population. Although proteolytic processing, referred to as “ectodomain shedding,” is pivotal for induction of apoptosis by RCAS1, the proteases involved in RCAS1-dependent shedding remain unclear. Here we investigated proteases involved in RCAS1 shedding and the association between tumor protease expression and serum RCAS1 concentration in uterine cancer patients. A disintegrin and metalloproteinase (ADAM) 9 was shown to be involved in the ectodomain shedding of RCAS1. Given the significant correlation between tumor ADAM9 expression and serum RCAS1 concentration in both cervical and endometrial cancer as well as the role for ADAM9 in RCAS1 shedding, further
Recombinant Human Tumor-associated Calcium Signal Transducer 2/TROP-2 (C-Fc)|| Human Tumor-associated Calcium Signal Transducer 2/TROP-2 (C-Fc)|| Tumor-associated Calcium Signal Transducer 2/TROP-2 (C-Fc)
The human 5T4 oncofoetal antigen is expressed by all types of trophoblast in pregnancy but is not detected on most adult tissues, although low levels are found on some epithelia. However, this antigen is strongly expressed by many cancers and tumour-associated labelling correlates with metastatic spread and poor clinical outcome for patients with gastric and colon cancer. Over-expression of the gene influences cell adhesion, shape and motility, which may be related to changes in the cellular localisation of the 5T4 oncofoetal antigen as malignancy develops. To establish whether the 5T4 oncofoetal antigen can serve as a tumour-specific marker for oral cancer and precancer, we have evaluated the pattern of expression on biopsies of normal, inflamed and dysplastic oral mucosa using immunohistochemistry. Oral mucosa, taken from different sites in the mouth, expressed the 5T4 oncofoetal antigen with varying intensity and pattern. The majority of the immunoreactivity was detected in the basal and ...
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject areas.
The biologic and clinical significance of the oncofetal antigens carcinoembryonic antigen (CEA) and alpha1-fetoprotein (AFP) are discussed. Although the current assays for these molecules are not tumor-specific, measurement of these molecules in the circulation of cancer patients is useful either for tumor diagnosis or for management of the cancer patient in the postoperative or post-chemotherapy state. An approach to increasing the specificity of the CEA radioimmunoassay is described. ...
Haughton, G; Lanier, L L.; Babcock, G F.; Lynes, D M.; and willexploit, N., Ation of the surface idiotype as tumor specific antigen. (1978). Subject Strain Bibliography 1978. 2066 ...
Liang, W and Cohen, E P., Detection of thymus leukemia antigens on the surface membranes of murine leukemia cells resistant to thymus leukemia anti- bodies and guinea pig complement. (1977). Subject Strain Bibliography 1977. 2311 ...
As a leading supplier of innovative life science research tools, Creative Diagnostics continues to expand its products portfolio by offering of unique antigens for researchers globally, which is supported by extensive research, development, and validation for superior quality. The addition of antigen products and services will enable scientists to work on more specific projects, and also provide leading researchers and diagnostic manufacturers with a more diverse antigen selection, which facilitates the development of assays with greater specificity and sensitivity.. These newly released antigens are rigorously tested to meet the demand in research and development and are featured with excellent quality, including Viral Antigens, Bacterial Antigens, Fungal Antigens, Parasitic Antigens, Immunoglobulin, Hapten, Cardiac Biomarkers and so on. With this expanded offering of antigens products, Creative Diagnostics enables scientists to achieve more complete analysis experiments. These products along ...
Many patients develop tumor antigen-specific T cell responses detectable in peripheral blood mononuclear cells (PBMCs) following cancer vaccine. However, measurable tumor regression is observed in a limited number of patients receiving cancer vaccines. There is a need to re-evaluate systemically the immune responses induced by cancer vaccines. Here, we established animal models targeting two human cancer/testis antigens, NY-ESO-1 and MAGE-A4. Cytotoxic T lymphocyte (CTL) epitopes of these antigens were investigated by immunizing BALB/c mice with plasmids encoding the entire sequences of NY-ESO-1 or MAGE-A4. CD8(+) T cells specific for NY-ESO-1 or MAGE-A4 were able to be detected by ELISPOT assays using antigen presenting cells pulsed with overlapping peptides covering the whole protein, indicating the high immunogenicity of these antigens in mice. Truncation of these peptides revealed that NY-ESO-1-specific CD8(+) T cells recognized D(d)-restricted 8mer peptides, NY-ESO-181-88. MAGE-A4
In developed countries, colorectal cancer (CRC) is a leading cause of cancer. Because this disease develops slowly over years and often starts with the apparition of polyps that may evolve in a malignant tumor, this cancer is particularly suitable for screening. However, current techniques of detection lack specificity and sensitivity, or are invasive, reducing the compliance of the patients. Thus, there is a need to find new biomarkers to improve the detection of CRC at an early stage and to reduce its incidence. In this work, we focused on autoantibodies (aAb) produced by the immune system as potential CRC biomarkers since they combine several advantages including stability, specificity and early production in the course of the disease. Human tumor-associated antigens (TAA) of interest were identified by the serological proteome analysis (SERPA) approach, based on the combination of 2D-gel electrophoresis and after transfer onto membranes, immunoblotting with sera from tumor-bearing mice or ...
Cancer testis (CT) antigens are promising targets for cancer immunotherapies such as cancer vaccines and genetically modified adoptive T cell therapy. In this study, we evaluated the expression of three CT antigens, melanoma-associated antigen A4 (MAGE-A4), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) and sarcoma antigen gene (SAGE). MAGE-A4, NY-ESO-1 and/or SAGE antigen expression in tumour samples was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Informed consent was obtained from individuals prior to study enrolment. In total, 585 samples in 21 tumour types were evaluated between June 2009 and March 2018. The positive expression rates of these CT antigens were as follows: MAGE-A4, 34.6% (range, 30.7-38.7); NY-ESO-1, 21.0% (range, 17.2-25.1); and SAGE, 21.8% (range, 18.5-25.4). The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; the NY-ESO-1 antigen was
Sperm protein (Sp17) is an attractive target for ovarian cancer (OC) vaccines because of its over-expression in primary as well as in metastatic lesions, at all stages of the disease. Our studies suggest that a Sp17-based vaccine can induce an enduring defense against OC development in C57BL/6 mice with ID8 cells, following prophylactic and therapeutic treatments. This is the first time that a mouse counterpart of a cancer testis antigen (Sp17) was shown to be expressed in an OC mouse model, and that vaccination against this antigen significantly controlled tumor growth. Our study shows that the CpG-adjuvated Sp17 vaccine overcomes the issue of immunologic tolerance, the major barrier to the development of effective immunotherapy for OC. Furthermore, this study provides a better understanding of OC biology by showing that Th-17 cells activation and contemporary immunosuppressive T-reg cells inhibition is required for vaccine efficacy. Taken together, these results indicate that prophylactic and ...
The first tumor-specific shared antigens and the cancer-germline genes that code for these antigens were identified with antitumor cytolytic T lymphocytes obtained from cancer patients. A few HLA class I-restricted antigenic peptides were identified by this direct approach. A large set of additional cancer-germline genes have now been identified by purely genetic approaches or by screening tumor cDNA expression libraries with the serum of cancer patients. As a result, a vast number of sequences are known that can code for tumor-specific shared antigens, but most of the encoded antigenic peptides have not yet been identified. We review here recent reverse immunology approaches for the identification of new antigenic peptides. They are based on in vitro stimulation of naive T cells with dendritic cells that have either been loaded with a cancer-germline protein or that have been transduced with viruses carrying cancer-germline coding sequences. These approaches have led to the identification of many
A number of human tumor antigens have been characterized recently using cytolytic T lymphocytes (CTL) as screening tools. Some of them are encoded by MAGE-type genes, which are silent in normal tissues except in male germ cells, but are activated in a variety of tumors. These tumor-specific shared antigens appear to be promising targets for cancer immunotherapy. However, the choice of these antigens as targets has been questioned because of the lack of direct evidence that in vivo responses against such antigens can lead to tumor rejection. The antigen encoded by the mouse gene P1A represents the only available animal model system for MAGE-type tumor antigens. We show here that mice immunized by injection of L1210 leukemia cells expressing P1A and B7-1 (L1210.P1A.B7-1) are efficiently protected against a challenge with a lethal dose of mastocytoma P815 tumor cells, which express P1A. Mice immunized with L1210 cells expressing B7-1 but not P1A were not protected. Furthermore, we observed that P1A
Using the TCGA data set for malignant melanoma, the patients were segregated according to the presence or absence of the T cell-inflamed gene expression signature in the tumor microenvironment. Transcriptional profiling revealed no differences in the levels of cancer-testis (CT) antigens or differentiation antigens between the hot and the cold tumors. Using exome sequencing of tumor versus germline, a range of 18 to 3001 of non-synonymous mutations was observed in both cohorts. Using the syfpeithi algorithm for HLA-A*0201 patients, a median of 123 mutations having a high immunogenicity score were found in the T cell-inflamed cohort versus 176 in the non-T cell-inflamed. To confirm actual immunogenicity, 321 peptides from hot tumors and 409 peptides from cold tumors have been synthesized. Using a high-throughput T2 binding assay, peptides from both cohorts were found to bind to HLA-A*0201. In vitro priming of T cells using autologous dendritic cells also revealed that peptides from both cohorts ...
Abstract Background The lack of sufficient specificity and sensitivity among conventional cancer biomarkers, such as prostate specific antigen (PSA) for prostate cancer has been widely recognized after several decades of clinical implications. Autoantibodies (autoAb) among others are being extensively investigated as potential substitute markers, but remain elusive. One major obstacle is the lack of a sensitive and multiplex approach for quantifying autoAb against a large panel of clinically relevant tumor-associated antigens (TAA). Methods To circumvent preparation of phage lysates and purification of recombinant proteins, we identified B cell epitopes from a number of previously defined prostate cancer-associated antigens (PCAA). Peptide epitopes from cancer/testis antigen NY-ESO-1, XAGE-1b, SSX-2,4, as well as prostate cancer overexpressed antigen AMACR, p90 autoantigen, and LEDGF were then conjugated with seroMAP microspheres to allow multiplex measurement of autoAb present in serum samples. ...
Mass spectrometry helps identify antigens on tumor cells - posted in Immunology Products: Using an analytical technique called mass spectrometry (MS) that helps identify the chemical constitution of a substance, Angela M. Krackhardt and colleagues from Technische Universitat Munchen and collaborators identify novel target antigens for cancer intervention. Michal Bassani-Sternberg from Max Planck Institute of Biochemistry is the first author. CusAb offers protein. Immunotherapy works...
Alt. Names/Synonyms: ACSTD1; Adenocarcinoma-associated antigen; carcinoma-associated antigen GA733-2; Cell surface glycoprotein Trop-1; CO-17A; CO17-1A; DIAR5; EGP; EGP-2; EGP314; EGP34; EGP40; Ep-CAM; EPCAM; Epithelial cell adhesion molecule; Epithelial cell surface antigen; Epithelial glycoprotein; Epithelial glycoprotein 314; ESA; GA733-2; hEGP-2; hEGP314; HNPCC8; human epithelial glycoprotein-2; KS 1/4 antigen; KS1/4; KSA; M1S2; M4S1; Major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein); MIC18; MK-1; TACST-1; TACSTD1; TROP1; Tumor-associated calcium signal transducer 1 ...
Cancer treatment vaccines are designed to treat cancers that have already developed rather than to prevent them in the first place. Cancer treatment vaccines contain cancer-associated antigens to enhance the immune systems response to a patients tumor cells. The cancer-associated antigens can be proteins or another type of molecule found on the surface of or inside cancer cells that can stimulate B cells or killer T cells to attack them.. Some vaccines that are under development target antigens that are found on or in many types of cancer cells. These types of cancer vaccines are being tested in clinical trials in patients with a variety of cancers, including prostate, colorectal, lung, breast, and thyroid cancers. Other cancer vaccines target antigens that are unique to a specific cancer type (7-14). Still other vaccines are designed against an antigen specific to one patients tumor and need to be customized for each patient. The one cancer treatment vaccine that has received FDA approval, ...
PURPOSE: NY-ESO-1, one of the most immunogenic tumor antigens, is expressed in 15% to 25% of metastatic prostate cancers. The immunological and clinical effects of vaccination with recombinant NY-ESO-1 protein combined with CpG as adjuvant were evaluated. EXPERIMENTAL DESIGN: In a phase I clinical study, patients with advanced prostate cancer were vaccinated with recombinant NY-ESO-1 protein (100 μg) mixed with CpG 7909 (2.5 mg) every 3 weeks intradermally for 4 doses. Objectives of the study were the safety of the vaccine and changes of specific humoral and cellular immunological responses to NY-ESO-1 in relation to detectable NY-ESO-1 expression in the individual tumor. RESULTS: All 12 baseline sero-negative patients developed high-titer NY-ESO-1 antibody responses. B-cell epitope mapping identified NY-ESO-1 p91-110 to be recognized most frequently by vaccine-induced antibodies. Two patients developed significant antibody titers against the adjuvant CpG. NY-ESO-1-specific CD4+ and/or CD8+ ...
Cancer-Testis Antigens: -Smart- Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
The isolation of CD8+ cytolytic T cells (CTL) reactive to the autologous tumors in cancer patients has allowed, during the last decade, the identification of several categories of tumor-associated antigens that can be the target of tumor-specific immune responses. Among them, one of the most relevant for the development of cancer vaccines is the group of the so-called Cancer-Testis (CT) antigens, which are expressed by tumor cells but not by most somatic adult tissues, with the exception of testis. Because of their expression commonly found in tumors of various histological types, CT antigen-derived peptides recognized by tumor reactive CTL are relevant candidates for generic vaccination of cancer patients.. In the last two years, we have analyzed the natural response to four CT antigen-derived HLA-A2 restricted epitopes recognized by tumor reactive CTL. Three of them correspond to the previously described peptides from MAGE-A10 (254-262), NY-ESO-1 (157-165) and CAMEL (1-11). The fourth peptide ...
This gene is a member of the melanoma antigen gene (MAGE) family. Most of the genes of this family encode tumor specific antigens that are not expressed in normal adult tissues except testis. Although the protein encoded by this gene shares strong homology with members of the MAGE family, it is expressed in almost all normal adult tissues. This gene has been demonstrated to be involved in the p75 neurotrophin receptor mediated programmed cell death pathway. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008 ...
In this issue of Clinical Cancer Research, a new development in adoptive T-cell therapy experimental mouse tumor model is reported by Leisegang and colleagues (1).. In retrospect, the 1990s were considered a golden period for tumor immunology when many tumor antigens recognized by T cells were identified. The antigens reported by Boon and colleagues in both murine and human cancers (2, 3) were derived from genes that are overexpressed in cancer and fetal tissues (4). The second class of unmutated antigens recognized by tumor-reactive T cells is tissue-specific antigens that are also found in tumor cells (5). These unmutated tumor antigens were favored for cancer vaccines and cancer therapy because they are present in a high proportion of human cancers. However, the classical study by Prehn and Main (6) has cast a long shadow on the utility of the shared tumor antigen, as their in vivo analysis showed that tumor rejection antigens are by and large individually specific. In supporting this notion, ...
Principal Investigator:ARAKI Nobuhito, Project Period (FY):1995 - 1997, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Orthopaedic surgery
Three of nine patients (33%) remain in complete clinical remission at 25, 38, and 52 months, respectively. The cancer-testis antigen NY-ESO-1 is expressed in greater than 40% of advanced epithelial ovarian cancers and represents a promising immunotherapeutic target. In a small Phase I (safety and immunogenicity) clinical trial conducted by Memorial Sloan-Kettering Cancer Center and…
There is clear evidence that tumor patients are able to generate TAA-specific T cell immunity spontaneously. Whereas the presence of tumor-specific T cells has been shown by many groups and for various tumor types, much less is known about the function of TAA-specific T cells in vivo. Most of the TAAs including differentiation, germ-line, and shared overexpressed antigens are not tumor specific but are also expressed at low levels in certain nonmalignant tissues. This should influence the type of T cell response because deletion of functional high-avidity self-reactive T cells in the thymus as well as peripheral deletion or anergy was shown in various animal models (reviewed in Ref. 74 ). There are a few recent studies analyzing the functional avidity of TAA-specific T cells in patients. In leukemia patients, low-avidity T cells to proteinase 3, which are able to kill leukemia cells, can readily be expanded. However, high-avidity T cells can also be expanded from patients in cytogenetic ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in cancer therapy but needs improvement for more effective treatment of solid tumors. While most clinical approaches have focused on CD8+ T cells, the importance of CD4+ T cells in mediating tumor regression has become apparent. Regarding shared (self) tumor antigens, it is unclear whether the human CD4+ T cell repertoire has been shaped by tolerance mechanisms and lacks highly functional TCRs suitable for therapy. Here, TCRs against the tumor-associated antigen NY-ESO-1 were isolated either from human CD4+ T cells or from mice that express a diverse human TCR repertoire with HLA-DRA/DRB1*0401 restriction and are NY-ESO-1 negative. NY-ESO-1-reactive TCRs from the mice showed superior recognition of tumor cells and higher functional activity compared with TCRs from humans. We identified a candidate TCR, TCR-3598_2, which was expressed in CD4+ T cells and caused tumor regression in combination with ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Background: This study aimed to assess the prognostic value of receptor binding cancer antigen expressed on SiSo cells (RCAS1) expression and host immune response in gastric carcinomas. Methods: We i
ASN004 is an Antibody Drug Conjugate (ADC) that targets the 5T4 oncofetal antigen (trophoblast glycoprotein), which is highly expressed in a wide range of malignant tumors, while having very limited expression in normal tissues. ASN004 incorporates a novel single-chain homo-dimer antibody, Fleximer® linker technology (Mersana Therapeutics), and several cytotoxic dolastatin (auristatin) analog warheads per ADC molecule (drug/antibody ratio ∼15). ASN004 shows high affinity for the 5T4 antigen and for 5T4-expressing tumor cells. As well, ASN004 shows potent cytotoxicity that is selective for 5T4-expressing tumor cells. ASN004 provides strong tumor regression and tumor-free survivors in multiple tumor xenograft models, at well-tolerated doses as low as 0.3 mg/kg iv. Furthermore, ASN004 causes tumor regression when administered to xenografts bearing more advanced (500 mm3) tumors. Robust, potent efficacy for ASN004 has also been demonstrated in head-to-head comparison studies with relevant ...
As mentioned earlier, another aspect of cancer is a failure of the immune system to recognize tumor specific antigens. Cytokines behave similarly to growth factors, causing cells to grow and divide; however, they are the predominant cellular signals of the immune system and have other actions such as attaching (chemotaxis) white blood cells to the site of an infection. Interestingly, it has been shown cancer cells signal suppressor T cells to protect them from killer T cells against unique tumor antigens. The mechanism of recruitment is not fully understood but TGF-b and interleukin 10 (IL-10) have been implicated in regulatory T cell function. While some cytokines play a role in suppressing the immune system, others such as IL-2 play a role in activating the immune system. One of the strategies in battling cancer has been to exploit the ability of interleukin-2 (IL-2) to heighten the immune response. IL-2 has been shown to cause complete remission in 6% of patients with renal cancer ...
We have shown that both regressor and progressor clones can be isolated from a UV regressor tumor, RD-1024. Although the daughter clones are characterized by differences in tumorigenic potential in normal transplant hosts, they nevertheless seem to express the same major tumor rejection antigens, because immunization with either the regressor parent tumor, RD-1024, or with regressor Cl 8 protects against subsequent challenge with progressor C1 4 or Cl 9. Consistent with the in vivo-generated data is the evidence that draining lymph node cells with functional specificity for regressor Cl 8 are capable of cross-reactive cytotoxicity in an in vitro chromium release assay. We have demonstrated an indirect interaction occurring in vivo between regressor and progressor cells, in that Cl 8 cells have the ability to influence the outcome of simultaneous or sequential challenge with Cl 4 or Cl 9 cells. Because 500 rad of gamma irradiation has been shown to compromise the ability of mice to respond to a ...
In 2001, we have started compiling what we thought were the most relevant human tumor antigens, and created a database. Each line corresponds to a peptide, considered to be a tumor antigen given that it is recognized by T lymphocytes that also recognize tumor cells expressing the parent protein.
Objective(s): Multi-epitopic protein vaccines and direction of vaccine delivery to dendritic cells (DCs) are encouraging approaches for enhancing immune system reactions against mutable pathogens. The very best cultivation condition for creation of HIVtop4 proteins can be induction by 1 mM IPTG during 4 hr in 2XYT moderate. The final focus of purified proteins was 500 g/ml. genome offers led to Vandetanib the introduction of vaccines incorporating just these essential epitopes to be able to elicit the mandatory immunologic response (5, 6). These epitope centered vaccines possess potential benefits like as biosafety, exact control over Vandetanib the disease fighting capability activation and capability of concentrate on conserved and extremely immunogenic antigen areas (7). Among the HIV-1 antigens, Gag, Tat, Env and Pol have obtained substantial interest because of the essential tasks in viral existence routine (8, 9), and also have sites in the viral genome mapping to both T helper and T ...
Cytolytic CD8 T cells fall into two subpopulations based on cytokine-secretion. Type 1 CD8 cells Tc1 characteristically secrete IFN-gamma, whereas type 2 CD8 cells Tc2 secrete ILA and IL- 5. Using a TSA mammary carcinoma cell line, expressing HA as a surrogate tumor-associated antigen, we assessed the therapeutic effects of adoptively transferred HA tumor-specific Tc1 and Tc2 effector cells in mice with established malignancy. Both Tc1 and Tc2 subpopulations effectively delayed tumor cell growth and mediated tumor regression in mice with established malignancy. Flow cytometric analysis showed that donor cells accumulated at the tumor site and antitumor effects were highly tumor specific. First-line treatment with either methotrexate MTX or 5-Fluorouracil 5-FU chemotherapeutic agents markedly enhanced the co- therapeutic effects of Tc2 effector cells. Whereas, MTX but not 5-FU, acted synergistically with corresponding Tc1 immunotherapy. Although effector cell therapies in combination with chemotherapy
PRP31_HUMAN RecName: Full=U4/U6 small nuclear ribonucleoprotein Prp31; AltName: Full=Pre-mRNA-processing factor 31; AltName: Full=Serologically defined breast cancer antigen NY-BR-99; AltName: Full=U4/U6 snRNP 61 kDa protein; Short=Protein 61K; Short=hPrp31 ...
Tikcro Technologies Ltd., powered by a novel 3D antigen design technology, generates new ‎antibodies that block receptor/ligand surface domains of immune modulators and re-‎activate the bodys immune system to fight cancer. Our antibodies are in various pre-‎clinical stages.. Following extensive collaborative research with the Weizmann Institute of Science in ‎Israel, we are developing drug-candidates by leveraging a unique antigen design ‎technology for the generation of new functional blocking antibodies. This approach has ‎shown early success with pipeline below. Going forward, in 2017-2018 we plan to advance ‎with early-stage candidates to rigorous pre-clinical trials and aim to build sufficient data for ‎further progress and clinical trials.‎. ...
Janelle, Valérie; Lamarre, Alain (2014). How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity? Frontiers in oncology , vol. 4 , nº 135. p. 1-3. DOI: 10.3389/fonc.2014.00135. ...
TROP2 belongs to the TACSTD family and is a cell surface glycoprotein encoded by the TACSTD2 gene. It is also known as tumor-associated calcium signal transducer 2 (TACSTD2), epidermal glycoprotein 1 (EGP-1), and gastrointestinal tumor-associated antigen (GA733-1) and surface mar
Alternative Name: ADAM Metallopeptidase Domain 2, Fertilin β, Cancer/Testis Antigen 15, Disintegrin And Metalloproteinase Domain-Containing Protein 2, PH30-Beta, FTNB, CT15, PH30, EC 3.4.24, PH-30b, CRYN1, CRYN2, PH-30 ...
Zdroj: Immunol Lett. 2020 Mar;219:46-53. doi: 10.1016/j.imlet.2020.01.001. Epub 2020 Jan 10. Authors: O. Palata, N. Podzimkova Hradilova, D. Mysiková, B. Kutna, H. Mrazkova, R. Lischke, R. Spisek, I. Adkins. ...
Squamous cell carcinoma antigen: a role in the early identification of nodal metastases in men with squamous cell carcinoma of the penis. To evaluate whether serum squamous cell carcinoma antigen (SCCAg) measurements may be of use in identifying nodal metastases in patients with SCC of the penis after treating the primary tumour. The levels of SCCAg were analysed in 11 men with penile SCC between 1994 and 2001. An elevated SCCAg level had a sensitivity of 57% (95% confidence interval, CI, 18-90%) and a specificity of 100% (CI 40-100%) for nodal metastases. Levels of SCCAg increased exponentially in patients who developed nodal metastases after treatment of the primary tumour, and were elevated before clinical or radiological evidence of nodal disease. Either the absolute level or the rate of rise of SCCAg may be a useful tool with which to follow patients after excision of the primary tumour. It may be more sensitive than computed tomography and magnetic resonanc imaging in detecting recurrence, ...
Our analysis of cervical cancer patients treated with CCRT indicated that the sensitivity and specificity of two consecutive increases in serum SCC-Ag for predicting tumor recurrence were 61.1% and 97.9%, respectively. These results are comparable to previously reported results. For example, several studies of cervical cancer patients showed that an elevated serum SCC-Ag level was associated with 70-92% rate of recurrent tumors [8, 11, 14-19]; in addition, the specificity of SCC-Ag during the follow-up period was quite high, varying from 95 to 98% [7, 16, 20]. According to our ROC analysis, the area under the ROC curve indicated the ΔSCC-Ag was 0.83 for patients who had elevated pre-treatment SCC-Ag. Therefore, our results indicate that ΔSCC-Ag had good clinical performance in detection of recurrent disease.. As described above, we defined biochemical failure as two consecutive SCC-Ag values above normal. There are no standard criteria used to define biochemical failure in cervical cancer, and ...
TY - JOUR. T1 - Carbonic anhydrase IX expression in renal neoplasms. T2 - Correlation with tumor type and grade. AU - Genega, Elizabeth M.. AU - Ghebremichael, Musie. AU - Najarian, Robert. AU - Fu, Yineng. AU - Wang, Yihong. AU - Argani, Pedram. AU - Grisanzio, Chiara. AU - Signoretti, Sabina. PY - 2010/12. Y1 - 2010/12. N2 - Carbonic anhydrase IX (CAIX), a hypoxia-induced protein, is expressed in some renal tumors. We evaluated its immunohistochemical expression in 317 primary and 42 metastatic renal neoplasms (186 clear cell, 52 papillary, 35 chromophobe, 47 unclassified, and 15 Xp11.2 translocation renal cell carcinomas [RCCs]; 26 oncocytomas; 2 metanephric adenomas; 1 urothelial carcinoma; 1 mixed epithelial and stromal tumor; and 1 angiomyolipoma); 7 neoplasms were unknown as to whether they were primary or metastatic. We also correlated expression with tumor type and grade. Variable staining was seen in clear cell, papillary, unclassified, and Xp11.2 translocation carcinomas. One ...
PURPOSE: To evaluate carbonic anhydrase (CA) IX as a surrogate marker of hypoxia and investigate the prognostic significance of different patterns of expression in non-small-cell lung cancer (NSCLC). METHODS: Standard immunohistochemical techniques were used to study CA IX expression in 175 resected NSCLC tumors. CA IX expression was determined by Western blotting in A549 cell lines grown under normoxic and hypoxic conditions. Measurements from microvessels to CA IX positivity were obtained. RESULTS: CA IX immunostaining was detected in 81.8% of patients. Membranous (m) (P =.005), cytoplasmic (c) (P =.018), and stromal (P |.001) CA IX expression correlated with the extent of tumor necrosis (TN). The mean distance from vascular endothelium to the start of tumor cell positivity was 90 micro m, which equates to an oxygen pressure of 5.77 mmHg. The distance to blood vessels from individual tumor cells or tumor cell clusters was greater if they expressed mCA IX than if they did not (P |.001). Hypoxic
TY - JOUR. T1 - Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. AU - Mortarini, Roberta. AU - Borri, Alessandra. AU - Tragni, Gabrina. AU - Bersani, Ilaria. AU - Vegetti, Claudia. AU - Bajetta, Emilio. AU - Pilotti, Silvana. AU - Cerundolo, Vincenzo. AU - Anichini, Andrea. PY - 2000/7/1. Y1 - 2000/7/1. N2 - Systemic effects on T-cell-mediated antitumor immunity, on expression of T-cell adhesion/homing receptors, and on the promotion of T-cell infiltration of neoplastic tissue may represent key steps for the efficacy of immunological therapies of cancer. In this study, we investigated whether these processes can be promoted by s.c. administration of low-dose (0.5 μg/kg) recombinant human interleukin-12 (rHuIL-12) to metastatic melanoma patients. A striking burst of HLA-restricted CTL precursors (CTLp) directed to autologous tumor was documented in peripheral blood by a ...
The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This encoded protein is thought to be involved in the regulation of mRNA splicing. [provided by RefSeq, Jul 2008 ...
TY - JOUR. T1 - Surface Marker Epithelial Cell Adhesion Molecule and E-cadherin Facilitate the Identification and Selection of Induced Pluripotent Stem Cells. AU - Chen, Hsin Fu. AU - Chuang, Ching Yu. AU - Lee, Wen Chih. AU - Huang, Hsiang Po. AU - Wu, Han Chung. AU - Ho, Hong Nerng. AU - Chen, Yu Ju. AU - Kuo, Hung Chih. PY - 2011/9/1. Y1 - 2011/9/1. N2 - The derivation of induced pluripotent stem cells (iPSCs) requires not only efficient reprogramming methods, but also reliable markers for identification and purification of iPSCs. Here, we demonstrate that surface markers, epithelial cells adhesion molecule (EpCAM) and epithelial cadherin (E-cadherin) can be used for efficient identification and/or isolation of reprogrammed mouse iPSCs. By viral transduction of Oct4, Sox2, Klf4 and n- or c-Myc into mouse embryonic fibroblasts, we observed that the conventional mouse embryonic stem cell (mESC) markers, alkaline phosphatase (AP) and stage-specific embryonic antigen 1 (SSEA1), were expressed in ...
Buy Psca recombinant protein, Prostate stem cell antigen Recombinant Protein-P57096.1 (MBS962351) product datasheet at MyBioSource, Recombinant Proteins
Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer.: We found that high P
Human being epithelial cell adhesion molecule (HEPCAM) is a tumor-associated antigen frequently expressed in carcinomas, which promotes proliferation after controlled intramembrane proteolysis. which can be connected with mutations from the gene (9). Although Lei (8) reported a particular amount of embryonic lethality, the nice known reasons for these obvious discrepancies in phenotypes stay unknown. Furthermore, molecular systems in charge of the noticed Bay 11-7821 congenital tufting enteropathy phenotypes had been deviating. Guerra (7) suggested a job for adherens junctions having a mislocalization of E-cadherin and -catenin in the developing intestine (7), whereas Lei (8) excluded the participation of E-cadherin and -catenin, which were located properly, and a function was stated by them for mEpcam in the recruitment Bay 11-7821 of claudins to tight junctions. A job for Epcam in the forming of practical adherens junctions via E-cadherin was further referred to during epiboly Rabbit ...
Cancer testis antigens (CTAs) are expressed in a variety of malignant tumors but not in any normal adult tissues except germ cells and occasionally placenta. Because of this tumor-associated pattern of expression, CTAs are regarded as potential vaccine targets. The expression of CTAs in gastrointestinal stromal tumors (GIST) has not been analyzed systematically previously. The present study was performed to analyze the expression of CTA in GIST and to determine if CTA expression correlates with prognosis. Thirty-five GIST patients were retrospectively analyzed for their expression of CTAs by immunohistochemistry using the following monoclonal antibodies (mAb/antigen): MA454/MAGE-A1, M3H67/MAGE-A3, 57B/MAGE-A4, CT7-33/MAGE-C1 and E978/NY-ESO-1. Fourteen tumors (40%) expressed 1 or more of the 5 CTAs tested. Fourteen percent (n = 5/35) were positive for MAGE-A1, MAGE-A3 or MAGE-A4, respectively. Twenty-six percent (n = 9/35) stained positive for MAGE-C1 and 20% (n = 7/35) for NY-ESO-1. A
As a leading supplier of innovative life science research tools, Creative Diagnostics continues to expand its products portfolio by offering of unique antigens for researchers globally, which is supported by extensive research, development, and validation for superior quality. The addition of antigen products and services will enable scientists to work on more specific projects, and also provide leading researchers and diagnostic manufacturers with a more diverse antigen selection, which facilitates the development of assays with greater specificity and sensitivity.. These newly released antigens are rigorously tested to meet the demand in research and development and are featured with excellent quality, including Viral Antigens, Bacterial Antigens, Fungal Antigens, Parasitic Antigens, Immunoglobulin, Hapten, Cardiac Biomarkers and so on. With this expanded offering of antigens products, Creative Diagnostics enables scientists to achieve more complete analysis experiments. These products along ...
Background: The delivery of specific immunotherapies for malignant tumours requires the identification of relevant tumour antigens and sequences from these which can be used to stimulate protective T cell-mediated immunity. HAGE (DDX43) is a cancer testis antigen belonging to the DEAD box family of helicases found by our group to be over-expressed in many solid cancers including breast cancer (Mathieu et al.1) immunogenic (Mathieu et al.2 and to be a biomarker for poor prognosis as well as a predictor of chemotherapy response in breast cancer (Abdel-fatah et al.3). We propose that HAGE might be a novel immunotherapeutic target for patients bearing breast cancers expressing this antigen. The aim of this study is to identify strongly immunogenic HAGE-derived sequences which can be used for the development of a therapeutic vaccine for HAGE positive cancer.. Experimental Design: The HAGE-derived sequences were identified and assessed after: (i) using a computer-based epitope predictive tool; (ii) ...
Human melanoma antigen (MAGE) genes have been shown to be expressed in both normal tissues and in various tumors and tumor related cells. Two types of MAGE genes have been characterized based on their expression: type-I members are silent in all normal tissues except for in the male germ line and placenta while type-II members are expressed ubiquitously in both tumor and normal cells (Figure 1). MAGE-C subfamily members are type-I genes expressed in various tumor types; their proteins are tumor-specific antigens that can be recognized by cytolytic T lymphocytes. MAGE-D subfamily members are type-II members they do not encode for those tumor-specific antigens seen in type-I MAGE and are also expressed ubiquitously in normal adult tissues. While MAGE genes could be targets for immunotherapy, information on the function and expression pattern of MAGE-C and MAGE D genes, however, remains incomplete. Analysis of the gene expression of type-I and type-II MAGE genes in various histological tumors may ...
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca2+-independent homotypic cell-cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. It appears to play a role in tumorigenesis and metastasis of carcinomas, so it can also act as a potential prognostic marker and as a potential target for immunotherapeutic strategies. First discovered in 1979, EpCAM was initially described as a dominant surface antigen on human colon carcinoma. Because of its prevalence on many carcinomas, it has been discovered many different times. EpCAM therefore has many aliases the most notable of which include TACSTD1 (tumor-associated calcium signal transducer 1), CD326 ...
A discovery by scientists working with the Health Sciences Initiative could lead the way to a vaccine against prostate cancer. The researchers, led by immunologist James Allison, a Howard Hughes Medical Institute investigator and professor of molecular and cell biology, found a protein on prostate cancer cells that tips off the immune system to the tumor s presence and brings in an armada of immune cells to destroy it.. If the protein, called an antigen, is truly unique to prostate cancer cells, it could lead to diagnostics for prostate cancer and a potential vaccine therapy against the disease, which is the second leading cause of cancer death in men, after lung cancer. This is the first prostate cancer antigen found.. The hope is twofold, Allison said. One, knowing what the specific target of the immune system is, we can do some very direct studies of whether it is a prognosticator of favorable outcome of disease. And two, we can start thinking about using the antigens to develop a specific ...
The human pancarcinoma-associated epithelial cell adhesion molecule (EpCAM) (EGP-2, CO17-1A) is a well-known target for carcinoma-directed immunotherapy. Mouse-derived mAbs directed to EpCAM have been used to treat colon carcinoma patients showing well-tolerable toxic side effects but limited antitu …
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Because tumor-specific cytotoxic T lymphocytes (CTL) recognize tumor antigen associated with MHC class I molecules expressed on the tumor surface, any alteration in the tumor antigen processing and presentation will greatly affect CTL immunity. In fact, downregulation or complete loss of MHC I molecules have been demonstrated in a wide array of tumors, particularly prostate, colon, lung, and breast cancers (5-12). Disruption or downregulation of antigen processing components, such as TAP (transporters associated with antigen processing) and LMP (components of the proteasome complex) genes have also been observed in several tumor types, including breast, prostate, and renal cancers (13-15). Another tactic tumors exploit is downregulation or alteration of tumor antigens. Several independent research groups described the loss of melanoma-associated antigen either during treatment by adoptive transfer of ex vivo expanded antigen-specific CTL (16) or during immune therapy by tumor vaccinations ...
Recombinant Human Epithelial cell adhesion molecule(EPCAM),partial von Cusabio bei SZABO-SCANDIC erhältlich. Weiteres zu Proteine & Peptide finden Sie hier.
Recombinant Human Epithelial cell adhesion molecule(EPCAM),partial von Cusabio bei SZABO-SCANDIC erhältlich. Weiteres zu Proteine & Peptide finden Sie hier.
NY-ESO-1 is a human tumor antigen of the cancer/testis family. It is highly expressed in many poor-prognosis melanomas. It is being studied as possible target for a cancer vaccine or immunotherapy. It is a target for some experimental engineered T-cell therapies for myeloma. Lloyd J. Old#Major Discoveries Gnjatic, S; et al. (2006). NY-ESO-1: review of an immunogenic tumor antigen. Advances in Cancer Research. 95: 1-30. doi:10.1016/S0065-230X(06)95001-5. PMID 16860654. van Rhee, F (15 May 2005). NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses (PDF). Blood. 105 (10): 3939-3944. doi:10.1182/blood-2004-09-3707. PMC 1895070 . PMID 15671442. Rapoport, AP; et al. (20 July 2015). NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine. 21 (8): 914-921. doi:10.1038/nm.3910. PMC 4529359 . PMID 26193344. A novel human-derived antibody against NY-ESO-1 ...
Y-box binding protein 2 (YBX2) has been associated with the properties of both germ cells and cancer cells. We hypothesized that YBX2 might contribute to the characteristics of cancer stem cells (CSCs). In this study, we clarified the function of YBX2 in endometrial cancer stem cells. We established a human YBX2-expressing Ishikawa (IK) cell line (IK-YBX2 cells). We analyzed gene expression associated with stemness and isolated SP cells from IK-YBX2 cells. The SP population of IK-YBX2 cells, the expression of ALDH1 and serial sphere-forming capacity were associated with levels of YBX2 expression. IK-YBX2 cells were resistant to anti-cancer drugs. In gene expression analysis, a gene for cancer testis antigen, CT45, was generally overexpressed in IK-YBX2 cells. YBX2-mediated CT45 expression was associated with increased levels of self-renewal capacity and paclitaxel resistance. The level of CT45 expression was enhanced in high-grade and/or advanced stages of human endometrial cancer tissues. We conclude
0192] Numerous tumor antigens are known in the art, including: (a) cancer-testis antigens such as NY-ESO-1, SSX2, SCP1 as well as RAGE, BAGE, GAGE and MAGE family polypeptides, for example, GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used, for example, to address melanoma, lung, head and neck, NSCLC, breast, gastrointestinal, and bladder tumors), (b) mutated antigens, for example, p53 (associated with various solid tumors, e.g., colorectal, lung, head and neck cancer), p21/Ras (associated with, e.g., melanoma, pancreatic cancer and colorectal cancer), CDK4 (associated with, e.g., melanoma), MUM1 (associated with, e.g., melanoma), caspase-8 (associated with, e.g., head and neck cancer), CIA 0205 (associated with, e.g., bladder cancer), HLA-A2-R1701, beta catenin (associated with, e.g., melanoma), TCR (associated with, e.g., T-cell non-Hodgkins lymphoma), BCR-abl (associated with, e.g., chronic myelogenous leukemia), triosephosphate isomerase, KIA ...
Treatment with the demethylating agent 5-Azacytidine leads to prolonged survival for patients with myelodysplastic syndrome, and the demethylation induces upregulation of cancer-testis antigens. Cancer-testis antigens are well-known targets for immune recognition in cancer, and the immune system may have a role in this treatment regimen. We show here that 5-Azacytidine treatment leads to increased T-cell recognition of tumor cells. T-cell responses against a large panel of cancer-testis antigens were detected before treatment, and these responses were further induced upon initiation of treatment. These characteristics point to an ideal combination of 5-Azacytidine and immune therapy to preferentially boost T-cell responses against cancer-testis antigens. To initiate such combination therapy, essential knowledge is required about the general immune modulatory effect of 5-Azacytidine. We therefore examined potential treatment effects on both immune stimulatory (CD8 and CD4 T cells and Natural ...
Gastric cancers are responsible for the second most cancer-related deaths worldwide. Although medical and surgical treatments have improved for gastric cancers, survival rates remain poor for both lung and gastric cancer patients.. Currently, approaches for immunotherapy in gastric cancer rely on the use of immunocytes, white blood cells that produce antibodies or trigger an immune response. Specifically, the current immunotherapy is designed to activate tumor specific cytotoxic T cells or to specifically bind target molecules or proteins expressed on the malignant tumor cells. In their research, a number of tumor rejection antigens have also been identified.. Experimental vaccination strategies are also in trial, including use of whole protein and peptide vaccines based on identification of peptides recognized by cytotoxic T lymphocytes and helper T lymphocytes. Tumor rejection antigens are selectively expressed in human tumors including gastric cancer, which can be recognized by cytotoxic T ...
TY - JOUR. T1 - MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. AU - Yang, Bing. AU - OHerrin, Sean M.. AU - Wu, Jianqiang. AU - Reagan-Shaw, Shannon. AU - Ma, Yongsheng. AU - Bhat, Kumar M.R.. AU - Gravekamp, Claudia. AU - Setaluri, Vijayasaradhi. AU - Peters, Noel. AU - Hoffmann, F. Michael. AU - Peng, Hongzhuang. AU - Ivanov, Alexey V.. AU - Simpson, Andrew J.G.. AU - Longley, B. Jack. N1 - Copyright: Copyright 2009 Elsevier B.V., All rights reserved.. PY - 2007/10/15. Y1 - 2007/10/15. N2 - The MAGE-A, MAGE-B, and MAGE-C protein families comprise the class-I MAGE/cancer testes antigens, a group of highly homologous proteins whose expression is suppressed in all normal tissues except developing sperm. Aberrant expression of class I MAGE proteins occurs in melanomas and many other malignancies, and MAGE proteins have long been recognized as tumor-specific targets; however, their functions have largely been unknown. ...
Human B melanoma antigen ELISA Kit;Human antigen MZ2-BA ELISA Kit;Human cancer/testis antigen 2.1 ELISA Kit;Human CT2.1 ELISA Kit;Human BAGE1 ELISA Kit;Human B melanoma antigen 1 ELISA Kit;Human cancer/testis antigen family 2, member 1 ELISA Kit ...
Vaccines that prevent disease have profoundly changed the lives of billions of people around the world, says Matthew M. Davis, M.D., MAPP, associate professor of pediatrics and internal medicine at the University of Michigan Medical School. A national strategy for therapeutic cancer vaccines would help emphasize development and regulatory approval for vaccines targeting cancers that currently do not have other good therapeutic options ...
Much has been learned in recent years concerning the nature of tumor antigens recognized by T cells. To apply this knowledge clinically, the nature of the host response to individual and multiple tumor antigens has to be characterized. This will help to define the efficacy of immune surveillance and the immune status of the host following exposure to tumor antigens expressed on pre-neoplastic tissue. To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. The single amino acid substitution in P91A results in the expression of a new MHC class I (H-2Ld)-binding peptide. In transgenic tissue, the H-2Ld/P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. We show that CD8+ T cell immune surveillance of P91A is ineffective without the introduction of a helper determinant operating ...
Complete cancer regression occurs in a subset of patients following adoptive T cell therapy (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs). However, the low success rate presents a great challenge to broader clinical application. To provide insight into TIL-based immunotherapy, we studied a successful case of ACT where regression was observed against tumors carrying the hotspot mutation G12D in the KRAS oncogene. Four T cell receptors (TCRs) made up the TIL infusion and recognized two KRAS-G12D neoantigens, a nonamer and a decamer, all restricted by human leukocyte antigen (HLA) C*08:02. Three of them (TCR9a, 9b, and 9c) were nonamer-specific, while one was decamer-specific (TCR10). We show that only mutant G12D but not the wild-type peptides stabilized HLA-C*08:02 due to the formation of a critical anchor salt bridge to HLA-C. Therapeutic TCRs exhibited high affinities, ranging from nanomolar to low micromolar. Intriguingly, TCR binding affinities to HLA-C inversely correlated ...
Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with established melanoma tumors. Successful tumor eradication was associated with the ability of mouse lymphoid cells to mount a tumor-specific CD4 + interleukin (IL)-17 recall response in vitro. We used this characteristic IL-17 response to screen the VSV-cDNA library and identified three different VSV-cDNA virus clones that, when used in combination but not alone, achieved the same efficacy against tumors as the complete parental virus library. VSV-expressed cDNA libraries can therefore be used to identify tumor rejection antigens that can cooperate to induce anti-tumor responses. This technology should be applicable to antigen discovery for other cancers, as well as for other diseases in which immune reactivity against more than one target antigen contributes to disease pathology. © 2012 Nature America, Inc. ...
The data presented here point to an active cooperation between CD4+ and CD8+ T cells in the eradication of tumor cells. The adoptive transfer of CD4+ T cells has been reported to treat established tumor (17, 18, 19); however, CD4+ T cells in these systems were hypothesized to act through NK or macrophage effector cells or by direct lysis of a MHC class II-positive tumor. Ossendorp et al. have found that generation of specific CD4+ T cells through immunization with a helper epitope resulted in increased anti-tumor activity that is mediated by CD8+ effector cells, even when the tumor cells used are MHC class II negative (20). The present manuscript is the first in which the transfer of CD4+ T cells specific for a model tumor Ag have been found to elicit the de novo generation of CD8+ T cells specific for that same Ag.. CD8+ T cells have been widely reported to transfer tumor immunity and to treat established tumors upon adoptive transfer (21, 22). They are thought to work by directly destroying ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
My research has focused on the discovery and clinical development of novel cancer immunotherapeutics targeting the self/tumor antigen guanylyl cyclase C (GUCY2C; GCC). Current research projects focus on:. 1. Cancer Mucosa Antigens as Immunotherapeutic Targets for Metastatic Tumors. Immunotherapy for human cancers is hindered, in part, by a lack of suitable target antigens. This is particularly relevant in tumors derived from mucosal tissues such as colorectal cancer, in which antigens that are sufficiently immunogenic, tumor-restricted and shared among patients are lacking, and for which conventional therapeutics are poorly efficacious. We have explored a novel class of tumor-associated antigens fulfilling these criteria by exploiting immune compartmentalization, which restricts cross-talk between systemic and mucosal immune compartments. This compartmentalization limits systemic tolerance to mucosa-restricted self-antigens and shields mucosa from systemic autoimmune responses. Thus, a novel ...
Antibody Panel to Epithelial Cell Surface Antigen EpCAMAcris Antibodies offers a full range of thoroughly evaluated antibodies for specific detection…
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC - Pipeline Review, H1 2019
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. This MAGEA gene encodes a protein that is C-terminally truncated compared to other family members, and this gene can be alternatively interpreted to be a pseudogene. The protein is represented in this Gene record in accordance with the assumed protein-coding status defined in the literature. Read-through transcription exists between this gene and the upstream melanoma antigen family A, 10 (MAGEA10) gene.
NY-ESO-1 and LAGE-1 are cancer testis antigens with an ideal profile for tumor immunotherapy, combining up-regulation in many cancer types with highly restricted expression in normal tissues and sharing a common HLA-A*0201 epitope, 157-165. Here, we present data to describe the specificity and anti-tumor activity of a bifunctional ImmTAC, comprising a soluble, high-affinity T-cell receptor (TCR) specific for NY-ESO-1157-165 fused to an anti-CD3 scFv. This reagent, ImmTAC-NYE, is shown to kill HLA-A2, antigen-positive tumor cell lines, and freshly isolated HLA-A2- and LAGE-1-positive NSCLC cells. Employing time-domain optical imaging, we demonstrate in vivo targeting of fluorescently labelled high-affinity NYESO-specific TCRs to HLA-A2-, NYESO- 1157-165-positive tumors in xenografted mice. In vivo ImmTAC-NYE efficacy was tested in a tumor model in which human lymphocytes were stably co-engrafted into NSG mice harboring tumor xenografts; efficacy was observed in both tumor prevention and ...
Sigma-Aldrich offers abstracts and full-text articles by [Achim A Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao-Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd J Old, Hearn Jay Cho].
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
Tumor-associated antigens (TAA) are monomorphic self-antigens that are proposed as targets for immunotherapeutic approaches to treat malignancies. We investigated whether T cells with sufficient avidity to recognize naturally overexpressed self-antigens in the context of self-HLA can be found in the T-cell repertoire of healthy donors. Minor histocompatibility antigen (MiHA)-specific T cells were used as model, as the influence of thymic selection on the T-cell repertoire directed against MiHA can be studied in both self (MiHApos donors)and non-self (MiHAneg donors) backgrounds. T-cell clones directed against the HLA*02:01-restricted MiHA HA-1H were isolated from HA-1Hneg/HLA-A*02:01pos and HA-1Hpos/HLA-A*02:01pos donors. Of the 16 unique HA-1H-specific T-cell clones, 5 T-cell clones derived from HA-1Hneg/HLA-A*02:01pos donors and 1 T-cell clone derived from an HA-1Hpos/HLA-A*02:01pos donor showed reactivity against HA-1Hpos target cells. Additionally, in total 663 T-cell clones (containing at ...
The human MAGE genes are expressed in a wide variety of tumors but not in normal cells, with the exception of the male germ cells, placenta, and, possibly, cells of the developing embryo. These genes encode tumor-specific antigens recognized by cytolytic T lymphocytes. The MAGE genes are located on …
By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells ... A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with ... an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. ...
... integumentary system List of target antigens in pemphigoid List of target antigens in pemphigus The most common benign neoplasm ... The most common malignant neoplasm is a basal cell carcinoma. Bolognia, Jean L.; et al. (2007). Dermatology. St. Louis: Mosby. ...
... making it possible to use the presence of the antigen to distinguish these conditions from B cell neoplasms. Due to its ... CD2+Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... It has also been called T-cell surface antigen T11/Leu-5, LFA-2, LFA-3 receptor, erythrocyte receptor and rosette receptor. It ... Luzzati AL, Giacomini E, Giordani L, Pugliese O, Viora M, Chersi A (1992). "The antigen-specific induction of normal human ...
... or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic ... Proliferating cell nuclear antigen (PCNA) is a DNA clamp that acts as a processivity factor for DNA polymerase δ in eukaryotic ... PCNA was originally identified as an antigen that is expressed in the nuclei of cells during the DNA synthesis phase of the ... "Entrez Gene: PCNA proliferating cell nuclear antigen". Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Dalla ...
List of specialized glands within the human integumentary system List of target antigens in pemphigoid List of target antigens ... Many cutaneous neoplasms occur in the setting of systemic syndromes. List of cutaneous conditions List of contact allergens ...
... may lead to secondary neoplasms in the patient.[citation needed] Topoisomerase I is the antigen recognized by Anti Scl-70 ...
Normally, B-cells take up foreign antigens, move to the germinal centers of secondary lymphoid organs such the spleen and lymph ... Lymphoid neoplasms with plasmablastic differentiation were classified by the World Health Organization, 2017 as a sub-grouping ... In cases so infected, the lymphoid neoplasm may result, at least in part, from this viral infection and therefore can be ... The lymphoid neoplasms with plasmacytic differentiation are: 1) Plasmablastic lymphoma: The most common of these lymphoid ...
There are many types of connective tissue disorders, such as: Connective tissue neoplasms including sarcomas such as ... providing the ground for starting inflammatory and immune responses upon the detection of antigens. ...
... and it is at this latter stage that CD3 antigen begins to migrate to the cell membrane. The antigen is found bound to the ... and can therefore be used to distinguish them from superficially similar B-cell and myeloid neoplasms. Zheng L, Lin J, Zhang B ... Mouse CD Antigen Chart Human CD Antigen Chart. ... The antigen remains present in almost all T-cell lymphomas and ... ISBN 978-1-4377-1528-6. Media related to CD3 (immunology) at Wikimedia Commons CD3+Antigens at the US National Library of ...
CD1+Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Mouse CD Antigen Chart Human CD Antigen ... CD4 continues to be expressed in most neoplasms derived from T helper cells. It is therefore possible to use CD4 ... The antigen has also been associated with a number of autoimmune diseases such as vitiligo and type I diabetes mellitus. T- ... CD4 is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The ...
Manolios N, Kemp O, Li ZG (1994). "The T cell antigen receptor alpha and beta chains interact via distinct regions with CD3 ... Dyer MJ (1989). "T-cell receptor delta/alpha rearrangements in lymphoid neoplasms". Blood. 74 (3): 1073-83. doi:10.1182/blood. ... Chilson OP, Kelly-Chilson AE (1989). "Mitogenic lectins bind to the antigen receptor on human lymphocytes". Eur. J. Immunol. 19 ...
As a weak, biphasic antibody, it absorbs to the P antigen in the cold temperature as in the periphery in the primary phase, and ... as well as hematological malignancies including non-Hodgkin lymphoma and myeloproliferative neoplasms. The exact pathogenesis ... Indirect DL test with addition of ABO-compatible P antigen-positive blood can be performed in case the direct DL test is ... The hallmark feature is the formation of polyclonal IgG autoantibody against the P antigen, which is a polysaccharide surface ...
All of these antigens are present in specific neuronal cell types. With these we can define anatomical circuits with a high ... In pathological conditions was also reported that glial neoplasms and reactive glial cells expressed this marker. Calretinin is ... Neuronal Nuclei antigen (NeuN) or Fox-3 is a nuclear protein present in postmitotic cell, at the point of differentiation into ... Lavezzi, A. M.; Corna, M. F.; Matturri, L. (2013). "Neuronal nuclear antigen (NeuN): a useful marker of neuronal immaturity in ...
Another important surface antigen is CD319 (SLAMF7). This antigen is expressed at high levels on normal human plasma cells. It ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... After leaving the bone marrow, the B cell acts as an antigen-presenting cell (APC) and internalizes offending antigens, which ... Pieces of the antigen (which are now known as antigenic peptides) are loaded onto MHC II molecules, and presented on its ...
In humans, pDCs exhibit plasma cell morphology and express CD4, HLA-DR, CD123, blood-derived dendritic cell antigen-2 (BDCA-2 ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... Unlike myeloid dendritic cells, myeloid antigens like CD11b, CD11c, CD13, CD14 and CD33 are not present on pDC surfaces. ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ...
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (August 2011). "T cells with chimeric antigen receptors have ... Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the ... Porter DL, Levine BL, Kalos M, Bagg A, June CH (August 2011). "Chimeric antigen receptor-modified T cells in chronic lymphoid ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ...
Tumor cells, however are highly abnormal, and many display unusual antigens. Some such tumor antigens are inappropriate for the ... Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies ... Humanised antibodies bind antigen much more weakly than the parent murine monoclonal antibody, with reported decreases in ... Increases in antibody-antigen binding strength have been achieved by introducing mutations into the complementarity determining ...
List of specialized glands within the human integumentary system List of target antigens in pemphigoid List of target antigens ... associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms ... of genes mutated in cutaneous conditions List of genes mutated in pigmented cutaneous lesions List of human leukocyte antigen ...
Balzar M, Winter MJ, de Boer CJ, Litvinov SV (October 1999). "The biology of the 17-1A antigen (Ep-CAM)". Journal of Molecular ... Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for ... Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (July 2004). "The carcinoma-associated antigen EpCAM upregulates c-myc ... Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (April 1994). "Ep-CAM: a human epithelial antigen is a homophilic ...
... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... It mediates at least in part the cell proliferating signaling stimulated by PDGF receptors as well as by antigen receptors on T ... Like the latter neoplasm, hematologic neoplasms cause by ETV6-JAK2 and BCR-JAK2 are aggressive and progress rapidly. Too few ... The FLT3 gene codes for the cluster of differentiation antigen 135 (i.e. CD135) protein or FLT3 protein. This protein is a ...
Neoplasms of the endolymphatic sac are very rare tumors. This article incorporates text in the public domain from page 1052 of ... Antigen diffusion from the perilymphatic space of the cochlea. Laryngoscope 1995; 105:623-628 Rask-Andersen H, Danckwardt- ...
Hemangiopericytoma is a rare vascular neoplasm, or abnormal growth, that may either be benign or malignant. In its malignant ... During the early proliferative phase (0-12 months) the tumors express proliferating cell nuclear antigen (pericytesna), ...
... system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms ... cutaneous lesions List of histologic stains that aid in diagnosis of cutaneous conditions List of human leukocyte antigen ...
... but calreticulin is not a Ro/SS-A antigen. Earlier papers referred to calreticulin as an Ro/SS-A antigen, but this was later ... which makes CALR mutations the second most common in myeloproliferative neoplasms. All mutations (insertions or deletions) ... This association prepares the MHC class I for binding an antigen for presentation on the cell surface. Calreticulin is also ... "A human Ro/SS-A autoantigen is the homologue of calreticulin and is highly homologous with onchocercal RAL-1 antigen and an ...
... system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... neoplasms, and cysts are skin lesions that develop from the epidermal layer of the skin. Aberrant basal cell carcinoma ... an overview with emphasis on the myeloid neoplasms". Chem. Biol. Interact. 184 (1-2): 16-20. doi:10.1016/j.cbi.2009.10.009. ... neoplasms invading or aberrantly present in the dermis. Acquired progressive lymphangioma (benign lymphangioendothelioma) Acral ...
Every helper T-cell is specific to one particular antigen. Only professional antigen-presenting cells (macrophages, B ... Blastic plasmacytoid dendritic cell neoplasm is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone ... Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They ... Here they act as antigen-presenting cells: they activate helper T-cells and killer T-cells as well as B-cells by presenting ...
... is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The ... CD4 continues to be expressed in most neoplasms derived from T helper cells. It is therefore possible to use CD4 ... Leucocyte typing: human leucocyte differentiation antigens detected by monoclonal antibodies: specification, classification, ... T cells displaying CD4 molecules (and not CD8) on their surface, therefore, are specific for antigens presented by MHC II and ...
The ability of T cells to recognize foreign antigens is mediated by the T-cell receptor. The T-cell receptor undergoes genetic ... ISBN 0-7020-2606-9. Huete-Garin, A.; S.S. Sagel (2005). "Chapter 6: "Mediastinum", Thymic Neoplasm". In J.K.T. Lee; S.S. Sagel ... Each T cell attacks a different antigen. T cells that attack the body's own proteins are eliminated in the thymus. Thymic ... This expression in the thymus, allows for the deletion of autoreactive thymocytes by exposing them to self-antigens during ...
Macrophages and lymphocytes show marked expression of HLA-DR antigen. Arguably XO is the bone localization of the ... Vankalakunti M, Saikia UN, Mathew M, Kang M (2007). Xanthogranulomatous osteomyelitis of ulna mimicking a neoplasm. World J ...
This is a type II immune response in which the drug binds to macromolecules on the surface of the RBCs and acts as an antigen. ... Less common causes of warm-type AIHA include neoplasms other than lymphoid, and infection. Secondary cold type AIHA is also ... The antibodies are usually directed against high-incidence antigens, therefore they also commonly act on allogenic RBCs (RBCs ... These reactions may result from unrelated antigen-antibody complexes that fix to an innocent-bystander erythrocyte, or from ...
Surface antigens[edit]. Terminally differentiated plasma cells express relatively few surface antigens, and do not express ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... Another important surface antigen is CD319 (SLAMF7). This antigen is expressed at high levels on normal human plasma cells. It ... After leaving the bone marrow, the B cell acts as an antigen presenting cell (APC) and internalizes offending antigens, which ...
... neoplasms including sarcomas such as hemangiopericytoma and malignant peripheral nerve sheath tumor in ... providing the ground for starting inflammatory and immune responses upon the detection of antigens.[15]:161 ...
2005). "Assessment of JC polyoma virus in colon neoplasms". Dis. Colon. Rectum. 48 (1): 86-91. doi:10.1007/s10350-004-0737-2. ... A map of the genome of JC virus, indicating the position of the tumor antigen genes (red), the three capsid protein genes ( ... Further research is needed to determine the exact etiological role of T-antigen, but there seems to be a connection to the ... T-antigen, also plays a key role in viral proliferation,[11] directing the initiation of DNA replication for the virus as well ...
... antigen - antigen presentation - antigen-presenting cell (APC) - antineoplastic - antiprotozoal - antiretroviral drugs - ... neoplasm - nephrotoxic - neuralgia - neurological complications of AIDS - neuropathy - neutralization - neutralizing antibody ... human leukocyte antigens (HLA) - human papilloma virus (HPV) - human T cell lymphotropic virus type I (HTLV-I) - human T cell ...
... of the immune system in response to specific antigens invading the body. The theory has become the widely accepted model for ... which act as a critical part of the immune response by specifically recognizing and binding to particular antigens, such as ... system responds to infection and how certain types of B and T lymphocytes are selected for destruction of specific antigens.[2] ...
Prostate specific membrane antigen is a transmembrane carboxypeptidase and exhibits folate hydrolase activity.[75] This protein ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... Prostate cancer screening is controversial.[1][3] Prostate-specific antigen (PSA) testing increases cancer detection but does ... Although the widespread use of prostate-specific antigen (PSA) screening in the US has resulted in diagnosis at earlier age and ...
Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors" ... "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): ... TdT is a protein expressed early in the development of pre-T and pre-B cells, whereas CALLA is an antigen found in 80% of ALL ... Chimeric antigen receptors (CARs) have been developed as a promising immunotherapy for ALL. This technology uses a single chain ...
... interacts with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ... Podust VN, Podust LM, Goubin F, Ducommun B, Huebscher U (1995). "Mechanism of inhibition of proliferating cell nuclear antigen- ... with proliferating cell nuclear antigen impedes negative growth control". J. Biol. Chem. 276 (4): 2766-74. doi:10.1074/jbc. ...
Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a tumor antigen) or on cells ... They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ...
"Neoplasms and cancer" has been chosen to reflect the fact that not all tumours are benign. The word "cancer" has been included ...
Antigens presented on MHC 1 molecules activates CD8+ T cells on keratinocytes or by encounters with activated CD4+ helper T ... Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ... An immune-mediated mechanism where basal keratinocytes are being targeted as foreign antigens by activated T cells, especially ... Autoimmune response to epithelial self-antigens remains a possibility. A single study of cutaneous LP reported evidence in ...
... and HLA-DR2 are examples of human leukocyte antigen types associated with aphthous stomatitis.[2][5] However, these HLA types ... Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ... or present a more substantial barrier to microbes and antigens, but this is unclear. Nicotine is also known to stimulate ...
"Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Molecular and ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ...
en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ... en:Prostate-specific antigen (26). *en:Proximal humerus fracture (3). *en:Pseudomonas aeruginosa (32) ...
Autoreactive thymic B cells are efficient antigen-presenting cells of cognate self-antigens for T cell negative selection., 110 ... Tseng-Tong Kuo, Classification of thymic epithelial neoplasms: a controversial issue coming to an end?, J.Cell.Mol.Med. 5. ... Ana C. Anderson ja Vijay K. Kuchroo, Expression of Self-antigen in the Thymus A Little Goes a Long Way, 1. detsember 2003 // ... Christian Koble ja Bruno Kyewski, The thymic medulla: a unique microenvironment for intercellular self-antigen transfer, J. Exp ...
嵌合抗原受體T細胞免疫療法(Chimeric Antigen Receptor T-Cell Immunotherapy)乃是先取得患者自身的T細胞後,在體外以基因工程的技術,使T細胞具有辨識癌細胞的能力後,再回輸到患者身上。被改造後的T細胞即稱為嵌合抗 ... Chapter 107: Neoplasms of the lung. (编) Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo
It has been suggested that the presence of antibodies to Streptococcus bovis/gallolyticus antigens or the antigens themselves ... Srikumar Chakravarthi; Baba Krishnan; Malathy Madhavan (1999). "Apoptosis and expression of p53 in colorectal neoplasms". ... Carcinoembryonic antigen blood level measurements follow the same timing, but are only advised for people with T2 or greater ... As summarized in the articles Carcinogenesis and Neoplasm, for sporadic cancers in general, a deficiency in DNA repair is ...
The Dalhousie researchers developed a way to deliver PZP antigens in liposomes, causing the release of antigens to be delayed. ... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... fertilization antigen 1 (FA-1), sp17, SOB2, A9D, CD52, YLP12, Eppin, CatSper, Izumo, sperm associated antigen 9 (SPAG9), 80 ... contemporary research has focused on searching for specific molecular antigens that are involved with sperm function. Antigens ...
... and cross-reactivity of tumor antigens and epidermal antigens. Once the molecules that hold the various levels of the membranes ... in association with an underlying neoplasm". A study concluded in 2009, summarized in 2010, surrounded the surgical removal of ... It is hypothesized that antigens associated with the tumor trigger an immune response resulting in blistering of the skin and ... Through immunoprecipitation, target antigens have been found to include desmoglein-3, desmoglein-1, envoplakin, periplakin, ...
Prostate-specific antigen-based prostate cancer screening: Past and future»։ International Journal of Urology 22 (6): 524-32։ ... Male Genitals - Prostate Neoplasms»։ Pathology study images։ University of Virginia School of Medicine։ Արխիվացված է օրիգինալից ... Prostate cancer screening with prostate-specific antigen: A guide to the guidelines»։ Prostate International 4 (4): 125-29։ ... Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel ...
"Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. ... However, it lacks sensitivity and specificity, not least because 5% of people lack the Lewis (a) antigen and cannot produce ... Pancreatic mucinous cystic neoplasms are a broad group of pancreas tumors that have varying malignant potential. They are being ... The third type, pancreatic mucinous cystic neoplasms (MCNs) mainly occur in women, and may remain benign or progress to cancer. ...
... with its levels either on the cell surface or in the serum increased in some neoplasms and decreased in others.[13] ... "Direct association of adenosine deaminase with a T cell activation antigen, CD26". Science. 261 (5120): 466-9. doi:10.1126/ ...
Denomme GA (2004). "The structure and function of the molecules that carry human red blood cell and platelet antigens". ...
An immunohistological study of the distribution of viral antigen within the brain". Journal of the Neurological Sciences. 54 (2 ... Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ...
"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms". N Engl J Med 369 (25): 2379-90. PMID 24325356. doi:10.1056/ ... "A human Ro/SS-A autoantigen is the homologue of calreticulin and is highly homologous with onchocercal RAL-1 antigen and an ... "Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2". N Engl J Med 369 (25): 2391-405. PMC 3966280 ...
Injection of sperm antigens causes inflammation of the testis (auto-immune orchitis) and reduced fertility. Thus, the blood- ... Testicular cancer and other neoplasms - To improve the chances of catching possible cases of testicular cancer or other health ... Mature sperm (and their antigens) arise long after immune tolerance is established in infancy. Therefore, since sperm are ...
Al-Toma A, Goerres MS, Meijer JW, Peña AS, Crusius JB, Mulder CJ (2006). "Human leukocyte antigen-DQ2 homozygosity and the ... also EATL is the most common neoplasm.[7] ...
腫瘤:內分泌腺腫瘤(C73-C75/D34-D35、193-194/226-227(英語:List of ICD-9 codes 140-239: neoplasms#Malignant neoplasm of other and unspecified ... Lewis antigen system),因此無法製造該蛋白。CA19-9診斷胰臟腺癌的靈敏度約80%,特異度約73%,靈敏度和特異度皆不夠高;比起用於診斷,該標記更適合用來追蹤已確診病人的病況[2][11]。 ... 最
1987: Hepatitis C virus, or HCV, discovered by panning a cDNA library made from diseased tissues for foreign antigens ... "A Transmissible Avian Neoplasm (Sarcoma of the Common Fowl)". Journal of Experimental Medicine. 12 (5): 696-705. doi:10.1084/ ... Because foreign virus antigens are expressed in these tumors, persons who are immunosuppressed such as AIDS or transplant ... the large T antigen (LT) is an analogue; LT also binds to several other cellular proteins, such as p107 and p130, on the same ...
Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters. By David M. Goldenberg, Hans J. ... Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters. By David M. Goldenberg, Hans J. ... Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters Message Subject. (Your Name) has ... Carcinoembryonic antigen, as measured by radioimmunoassay, is present in two different human colonic tumors that have been ...
Cyst fluid carcinoembryonic antigen level is not predictive of invasive cancer in patients with intraductal papillary mucinous ... neoplasm of the pancreas. Download Prime PubMed App to iPhone, iPad, or Android ... Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal ... Adenocarcinoma, MucinousAdultAgedAged, 80 and overCarcinoembryonic AntigenCarcinoma, Pancreatic DuctalCarcinoma, PapillaryCross ...
Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasms. Mehrdad Nadji, Seyed Z. Tabei, Albert Castro, T ... Prostatic‐specific antigen : An immunohistologic marker for prostatic neoplasms. / Nadji, Mehrdad; Tabei, Seyed Z.; Castro, ... title = "Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasms",. abstract = "Antiserum to a human ... specific antigen : An immunohistologic marker for prostatic neoplasms. In: Cancer. 1981 ; Vol. 48, No. 5. pp. 1229-1232. ...
Fetal antigens and cancer. Material type: Book; Format: print Publisher: London : Pitman, 1983Availability: Items available for ...
Antigens, Neoplasm. Grant support. *R01 CA134622-01A1/CA/NCI NIH HHS/United States ... The nature and site of tumor-antigen presentation to immune T cells by bone-marrow-derived cells within the tumor ... Marginating Dendritic Cells of the Tumor Microenvironment Cross-present Tumor Antigens and Stably Engage Tumor-Specific T cells ... Marginating Dendritic Cells of the Tumor Microenvironment Cross-present Tumor Antigens and Stably Engage Tumor-Specific T cells ...
Antigens, Neoplasm. LinkOut - more resources. Full Text Sources. *Elsevier Science. Other Literature Sources. *Cited by Patents ... Tumor antigens recognized by T cells.. Boon T1, Coulie PG, Van den Eynde B. ...
Neoplasm, Residual. Inflammation. Philadelphia Chromosome. Neoplasms by Histologic Type. Neoplasms. Lymphoproliferative ... CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies. The safety and ... CD19/CD22 chimeric antigen receptor (CAR) T cell properties [ Time Frame: Up to 15 years ]. Will explore correlations with CAR ... Biological: Chimeric Antigen Receptor T-Cell Therapy Drug: Cyclophosphamide Drug: Fludarabine Phosphate Other: Laboratory ...
Class I antigens are restricted to autologous astrocytoma cells. Class II antigens are shared by autologous as well as certain ... three classes of surface antigens have been defined. ... Antigens, Neoplasm / analysis* * Antigens, Surface / analysis* ... Class I antigens are restricted to autologous astrocytoma cells. Class II antigens are shared by autologous as well as certain ... Tumor-specific antigens Recent Results Cancer Res. 1980;75:1-9. doi: 10.1007/978-3-642-81491-4_1. ...
Prostatic Neoplasm. Intervention: Drug: abiraterone acetate in combination with prednisone. Participant Flow Hide Participant ... IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen. The safety and scientific validity of this study is the ... Percentage of Participants With Greater Than or Equal to (,=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) ... Percentage of Participants With Greater Than or Equal to (,=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) ...
Antigens, Neoplasm Grant support * DP2 OD002230/OD/NIH HHS/United States * R01 CA155010/CA/NCI NIH HHS/United States ... highlighting loss of antigen presentation and blockade of extrinsic apoptosis as key strategies of resistance to cytolytic ...
View mouse Cd79b Chr11:106311341-106314562 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
SPECC1L, sperm antigen with calponin homology and coiled-coil domains 1 like. Orthology source: HGNC, HomoloGene ... SPECC1L, sperm antigen with calponin homology and coiled-coil domains 1 like ...
Laryngeal Neoplasms. Urologic Neoplasms. Mouth Neoplasms. Lip Neoplasms. Tonsillar Neoplasms. Rare Diseases. Neoplasms, ... Breast Neoplasms. Neoplasms. Prostatic Neoplasms. Stomach Neoplasms. Rectal Neoplasms. Cholangiocarcinoma. Carcinoma, Renal ... Neoplasms by Histologic Type. Neoplasms by Site. Breast Diseases. Skin Diseases. Genital Neoplasms, Male. Urogenital Neoplasms ... Salivary Gland Neoplasms. Bile Duct Neoplasms. Carcinoma, Mucoepidermoid. Tongue Neoplasms. Adenocarcinoma, Mucinous. ...
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIGENS; COMPARATIVE EVALUATIONS; HAZARDS; HORMONES; METASTASES; NEOPLASMS; PATIENTS; ... Title: Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free ... Journal Article: Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse- ... in prostate cancer patients who achieved an undetectable prostate-specific antigen (PSA) after radical prostatectomy (RP). Here ...
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIGENS; BRACHYTHERAPY; DOSE RATES; HAZARDS; IODINE 125; METASTASES; MORTALITY; NEOPLASMS; ... Results: The median age of the patients was 67 years, and the median overall and prostate-specific antigen follow-up times were ...
Neoplasms. Ovarian Diseases. Adnexal Diseases. Genital Diseases, Female. Gonadal Disorders. Endocrine System Diseases. ... The purpose of this study is to evaluate the effect of oral contraceptive on the serum free prostatic specific antigen (PSA)in ... The purpose of this study is to evaluate the effect of oral contraceptive on the serum free prostatic specific antigen (PSA)in ... Study of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in ...
Tumour-associated transplantation antigens of neoplasms induced by a naturally occurring murine sarcoma virus (fbj-msv). ... Neoplasm:, Serology: Antigen, Transplantation:, Types of Tumors:, Rickettsia, Virus:, Strains: CBA, CBA/H-T6T6 ... Jones, D B. and Moore, M, "Tumour-associated transplantation antigens of neoplasms induced by a naturally occurring murine ...
The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer in DOAJ. DOAJ ... LCC Subject Category: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens ... total prostate-specific antigen, free prostate-specific antigen, prostate-specific antigen density, prostate cancer, benign ... The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer. Cancer ...
Prostate-specific membrane antigen (PSMA)-based radiopeptide/radioligand therapy represents a rapidly expanding field in the ... Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioimmunotherapy; ... BACKGROUND: Prostate-specific membrane antigen (PSMA)-based radiopeptide/radioligand therapy represents a rapidly expanding ... Aged; Aged, 80 and over; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Kallikreins; Lutetium; Male; Middle Aged; ...
Although prostate cancer screening by measurement of serum prostate-specific antigen (PSA) and digital rectal examination (DRE ... Neoplasm Staging. Odds Ratio. Palpation / methods*. Prostate-Specific Antigen*. Prostatic Neoplasms / blood, diagnosis*, ... Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a ... BACKGROUND: Although prostate cancer screening by measurement of serum prostate-specific antigen (PSA) and digital rectal ...
... tissue polypeptide-specific antigen (TPS), in 203 patients with non-small cell lung cancer (NSCLC), and related this to several ... Neoplasm Staging. Peptides / blood*. Prognosis. Regression Analysis. Tissue Polypeptide Antigen. Tumor Markers, Biological / ... In this study, we evaluated the prognostic value of the tumour marker, tissue polypeptide-specific antigen (TPS), in 203 ... 0/Peptides; 0/Tissue Polypeptide Antigen; 0/Tumor Markers, Biological; EC Dehydrogenase; EC ...
Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior. ... Antigen retrieval was performed in deparaffinized, rehydrated samples with 1 mM EDTA (pH 8.0) in microwave environment (3 × 5 ... It was initially gathered cases of epithelial salivary gland neoplasms that were surgically resected as the first therapeutic ... Among malignant neoplasms, there was graded frequency of positivity for CD105, with MEC being the highest (85.0%), followed by ...
Neoplasms 4 Flashcards Preview ESA 2- Mechanisms of Disease , Neoplasms 4 , Flashcards ... What % of malignant neoplasms are diagnosed in those over the age of 65? ... What % of malignant neoplasms are diagnosed in those under the age of 24? ... What factors should be considered when determining which individuals will have a favourable outcome for malignant neoplasms? ...
antigen processing and presentation - antigen processing and presentation of endogenous antigen - antigen processing and ... Antigen Processing and Presentation BIOCARTA. - Antigen processing and presentation KEGG. Data from KEGG and BioCarta [BIOCARTA ... In an independent primary DLBCL microarray data set, multiple MHC II genes, including human leukocyte antigen DR alpha chain ( ... Analysis of the individual genes demonstrated that MDA-MB-435 cells exhibited a higher tendency to metastasis and antigen ...
Prostate specific antigen and acinar density: a new dimension, the Prostatocrit. Prostate-specific antigen densities have ... Prostate - specific antigen (PSA) is a useful biomarker for detection of prostate cancer (PCa) and for risk classification in ... Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate- ... Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 - 100 ng / mL. ...
Ki-67 Antigen, Laryngeal Neoplasms, Male, Middle Aged, Prognosis, Tumor Suppressor Protein p53", ...
Intracytoplasmic antigen study by flow cytometry in hematolymphoid neoplasm. Intracytoplasmic antigen study by flow cytometry ... It has a non-debatable contribution to the diagnosis of hematolymphoid neoplasm as well as in minimal residual disease. ... Flow cytometric detection of intracellular antigens has become a standard method in establishing proper leukemic cell lineage ... Regarding the detection of intracellular antigens, standardization of the procedure remains, however, a real challenge. ...
... carbohydrate antigen 125 (CA125) and carbohydrate antigen 19-9 (CA19-9), in gastroenteropancreatic neuroendocrine neoplasm (GEP ... Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in ... Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 ... p,,b,OBJECTIVE,/b,To study the rate of elevated common biomarkers of digestive tumors, including carcinoembryonic antigen (CEA ...
0 (Antigens, Bacterial); 0 (Antigens, Neoplasm); 0 (Antigens, Viral); 0 (Biomarkers, Tumor); 0 (CTLA-4 Antigen); 0 (Epitopes, T ... 0 (Antigens, Bacterial); 0 (Drug Carriers); 0 (Escherichia coli Proteins); 0 (K88 antigen, E coli); 0 (Plant Lectins); 0 ( ... In the current study, we assessed serum IgA binding to the B. burgdorferi peptide antigens, C6, the target of the FDA-cleared ... After the second immunization, the antigen-specific CD4 cell responses for IFN-γ, IL-2, IL-4 and IL-10 were monitored by ...
0 (Antigens, Neoplasm); 0 (Reactive Oxygen Species). [Em] M s de entrada:. 1710. ... Neoplasms change over time through a process of cell-level evolution, driven by genetic and epigenetic alterations. However, ... The Evo- and Eco-indices provide a common lexicon for communicating about how neoplasms change in response to interventions, ...
  • Carcinoembryonic antigen, as measured by radioimmunoassay, is present in two different human colonic tumors that have been serially transplanted and maintained in the cheek pouches of unconditioned, adult golden hamsters. (
  • To study the rate of elevated common biomarkers of digestive tumors , including carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), carbohydrate antigen 125 (CA125) and carbohydrate antigen 19-9 (CA19-9), in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) and their prognostic values in GEP-NEN. (
  • Carcinoembryonic Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (
  • This graph shows the total number of publications written about "Carcinoembryonic Antigen" by people in Harvard Catalyst Profiles by year, and whether "Carcinoembryonic Antigen" was a major or minor topic of these publication. (
  • Below are the most recent publications written about "Carcinoembryonic Antigen" by people in Profiles. (
  • Hu Y, Huang Y, Wang Z, Wang Y, Ye X, Wong W, Li C, Sun D. Gold/WS2 nanocomposites fabricated by in-situ ultrasonication and assembling for photoelectrochemical immunosensing of carcinoembryonic antigen. (
  • Epithelial markers in primary skin cancer: an immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. (
  • We generated a fluorescent mouse model of spontaneous immunoevasive breast cancer and identified a subset of myeloid cells with significant similarity to dendritic cells and macrophages that constitutively ingest tumor-derived proteins and present processed tumor antigens to reactive T cells. (
  • Antibodies are large proteins called immunoglobulins (Igs) that bind to and remove the specific antigen. (
  • These stains are used to detect the presence, abundance, and localization of specific proteins to aid in determining the direction of differentiation in neoplasms with similar morphology as well as to provide prognostic or therapeutic information, among other applications. (
  • BACKGROUND: The Cancer/Testis Antigens (CTAs) are a heterogeneous group of proteins whose expression is typically restricted to the testis. (
  • In a more direct approach, murine bone marrow-derived DCs have been loaded with tumor antigen peptides (3 , 4) , antigenic proteins (5) , tumor lysates (6) , or tumor antigen genes (7) and have been shown in each case to stimulate antitumor activity when used to vaccinate naive mice. (
  • Antibodies are proteins that bind to antigens on harmful invaders in the body (eg, germs and viruses). (
  • Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. (
  • The basement membrane of basal cell carcinoma was characterized by indirect immunofluorescence using antibodies to laminin, type IV collagen, and bullous pemphigoid antigen, three distinct protein components of basement membrane. (
  • Two polyclonal rabbit antibodies to epithelial membrane antigen (EMA), two mouse monoclonal antibodies (E29 and HMFG-2), and a 'cocktail' of these two monoclonals have been compared using an indirect immunoperoxidase technique. (
  • Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. (
  • Expression of cDNA libraries from human melanoma, renal cancer, astrocytoma, and Hodgkin disease in Escherichia coli and screening for clones reactive with high-titer IgG antibodies in autologous patient serum lead to the discovery of at least four antigens with a restricted expression pattern in each tumor. (
  • Antibodies to a given antigen were usually confined to patients with the same tumor type. (
  • As a result, the mother's body could develop antibodies against the Rh antigen. (
  • Bi-specific antibodies, or BiTEs, are a type of monoclonal antibody that targets multiple antigens. (
  • This algorithm depicts the reflex path for the HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes assay (Test Code 91431). (
  • Plasmablasts, and to a greater extent, plasma cells make and secrete antibodies that bind the antigens to which their predecessor B-cells were previously exposed (see plasma cell differentiation). (
  • Antibodies function, in part, to neutralize harmful bacteria and viruses by binding antigens that are exposed on their surfaces. (
  • Due to their malignant nature, however, the plasmablasts in lymphoid neoplasms with plasmablastic differentiation do not mature into plasma cells or form antibodies but rather uncontrollably proliferate in and damage various tissues and organs. (
  • Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. (
  • To enhance the knowledge of medical society on the mucinous cystic neoplasms of the liver, here we aim to summarise contemporary data on these tumours, including the current definition and classification [ 1 ], the recent molecular genetic findings [ 3 , 4 ] as well as the practical issues of clinical presentation, diagnostic approach, treatment and prognosis. (
  • While basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are malignant neoplasms with a low lethality and a good prognosis [ 2 ], the 10-year survival rate is 92% among the patients with T1 melanomas, and is 50% in patients with T4 melanomas [ 3 ]. (
  • Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. (
  • Sato Y, Suzuki R, Takagi T, Sugimoto M and Ohira H: [Corrigendum] Circulating extracellular vesicle‑encapsulated microRNA as screening biomarkers for intraductal papillary mucinous neoplasm. (
  • Antiserum to a human prostate-specific antigen was raised in a rabbit and utilized by immunoperoxidase staining to evaluate its potential value as a diagnostic histologic marker for tumors of prostatic origin. (
  • In contrast to this specific defect in bullous pemphigoid antigen found in basal cell carcinoma, well-differentiated superficially invasive epidermal squamous cell carcinoma and several benign epidermal tumors (trichoepithelioma, wart, keratocanthoma, seborrheic keratosis, cylindroma) displayed all three antigens in the basement membrane that surrounded epithelial cell aggregates. (
  • Choroid plexus neoplasms are rare, intraventricular, primary central nervous system (CNS) tumors derived from choroid plexus epithelium that are seen predominantly in children. (
  • [ 2 , 3 ] In adults, they account for less than 1% of primary intracranial neoplasms, whereas choroid plexus tumors represent up to 5% of pediatric brain tumors, and up to 20% of those arising in children aged 1 year and younger. (
  • Tumors are also called neoplasms , which means that they are composed of new and actively growing tissue. (
  • Besides antigens known to elicit T-cell responses, such as MAGE-1 and tyrosinase, numerous additional antigens that were overexpressed or specifically expressed in tumors of the same type were identified. (
  • To validate the clinical usefulness of neutrophil-lymphocyte ratio (NLR) in discriminating real GS ≥ 7 PCa from biopsy-based GS ≤ 6 PCa in comparison with serum total prostate-specific antigen (tPSA) and value of their combination. (
  • This defect in bullous pemphigoid antigen may be due to abnormal synthesis by the tumor cells and could be related to the absence of differentiation of these cells. (
  • EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. (
  • Lymphoid neoplasms with plasmablastic differentiation were classified by the World Health Organization, 2017 as a sub-grouping of several distinct but rare lymphomas in which the malignant cells are B-cell lymphocytes that have become plasmablasts, i.e. immature plasma cells. (
  • The lymphoid neoplasms with plasmacytic differentiation are: 1) Plasmablastic lymphoma: The most common of these lymphoid neoplasms. (
  • What % of malignant neoplasms are diagnosed in those over the age of 65? (
  • What type of malignant neoplasms are most common in children younger than 14? (
  • What factors should be considered when determining which individuals will have a favourable outcome for malignant neoplasms? (
  • These molecules have an important role in tumoral progression, as well as in metastatic potential of some malignant neoplasms [ 4 , 5 ]. (
  • Expression of E-cadherin may be important in determining the invasive potential of epithelial neoplasms and the transition from benign to malignant neoplasms. (
  • The protein encoded by this gene associates with class II major histocompatibility complex (MHC) and is an important chaperone that regulates antigen presentation for immune response. (
  • An antigen is any substance (for example, a protein) that causes the immune system to respond. (
  • CD74 (HLA class II histocompatibility antigen gamma chain isoform b), is a transmembrane protein (on antigen presenting cells) which is the invariant chain that chaperones MHC class II dimers from the endoplasmic reticulum to the cell surface. (
  • Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. (
  • Prostate-specific membrane antigen (PSMA)-based radiopeptide/radioligand therapy represents a rapidly expanding field in the management of metastatic castrate-resistant prostate cancer (mCRPC). (
  • BACKGROUND: This study aims to analyze the prognostic importance of serum prostate specific antigen (PSA) response in patients who received radioligand therapy (RLT) with Lu-177 Prostate-specific membrane antigen (PSMA) for their castration-resistant prostate cancer. (
  • Soydal C, Araz M, Urun Y, Nak D, Ozkan E, Kucuk NO. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. (
  • Cholangiocarcinoma was the most commonly diagnosed neoplasm, followed by hepatocellular carcinoma and hemangiosarcoma. (
  • BACKGROUND: Although prostate cancer screening by measurement of serum prostate-specific antigen (PSA) and digital rectal examination (DRE) is common in clinical practice, the impact of such screening on prostate cancer-specific mortality remains uncertain. (
  • These campaigns advise the use of rectal examination accompanied by dosage of serum prostate specific antigen (PSA) levels in defined age groups. (
  • This finding shows that a human tumor-associated antigen can be produced in an animal host. (
  • Optimally, these interventions should be given when tumor-associated antigen (TAA) uptake and presentation peaks. (
  • This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating patients with CD19 positive diffuse large B-cell lymphoma or B acute lymphoblastic leukemia that has come back or does not respond to treatment. (
  • Lane and colleague Marlise Luskin, MD, MSCE, another BPDCN expert in the leukemia group, are excited to have opened the first cellular therapy protocol at Dana-Farber testing chimeric antigen receptor (CAR) T cells for BPDCN ( protocol 19-544 ). (
  • The assay showed low background and was sensitive for detecting antigen-specific T cells. (
  • We identified recurrently mutated genes that showed positive association with cytolytic activity, including beta-2-microglobulin (B2M), HLA-A, -B and -C and Caspase 8 (CASP8), highlighting loss of antigen presentation and blockade of extrinsic apoptosis as key strategies of resistance to cytolytic activity. (
  • Peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be administered emulsified in Incomplete Freund's Adjuvant, (IFA) to HLA-A201 patients with melanoma. (
  • Pituicytoma: characterization of a unique neoplasm by histology, immunohistochemistry, ultrastructure, and array-based comparative genomic hybridization. (
  • 192 ng/mL has proven accurate to differentiate mucinous from non-mucinous pancreatic cystic neoplasms. (
  • Mucinous cystic neoplasms of the liver and extrahepatic biliary tree have recently been re-defined by WHO as epithelial cystic tumours with ovarian-type mesenchymal stroma. (
  • Mucinous cystic neoplasms of the liver [ 1 ], formerly known as bile duct/biliary cystadenoma and biliary cystadenocarcinoma [ 2 ], represent an enigmatic entity, characterised by unknown origin and peculiar morphology including the presence of ovarian-type stroma. (
  • Currently, mucinous cystic neoplasms of the liver are defined as epithelial cystic tumours associated with ovarian-type mesenchymal stroma. (
  • Intraductal papillary mucinous tumor (IPMT) of the pancreas is a rare and unique form of pancreatic neoplasm characterized by proliferation of the epithelium lining the pancreatic ducts. (
  • Herein we report an extremely rare case of a combination intraductal papillary mucinous hyperplasia (IPMH) and endocrine neoplasm (islet cell tumor) of the pancreas. (
  • Synaptophysin is expressed by normal neuroendocrine cells and neuroendocrine neoplasms. (
  • It has a non-debatable contribution to the diagnosis of hematolymphoid neoplasm as well as in minimal residual disease . (
  • Implications for diagnosis of human neoplasms. (
  • This algorithm demonstrates how immunophenotyping test results can help with the differential diagnosis of lymphoid neoplasms. (
  • This is a study of a melanoma tumor antigen peptide vaccine. (
  • It was originally identified as a gene encoding a novel cancer-testis antigen that is over expressed in melanoma (Ikeda et al. (
  • Also referred to as MART1 (Melanoma Antigen Recognized by T cells). (
  • All primary and metastatic prostatic malignancies reacted positively, whereas nonprostatic neoplasms did not stain with this procedure. (
  • PURPOSE: Sialyl Tn (STn) antigen is a cancer-associated carbohydrate antigen expressed in cancers of the digestive tract. (
  • A prominent signature of the combination relates to the transcriptional induction of cancer testis antigens and genes involved in the immune response. (
  • Laboratory Evaluation of Suspected Lymphoid Neoplasm. (
  • 2) Plasmablastic plasma cell lymphoma or plasmablastic plasmacytoma: A lymphoid neoplasm that disseminates widely like the plasma cell lesions in multiple myeloma or is localized like the plasma cell lesions in plasmacytoma. (
  • 6) Human herpesvirus 8-positive diffuse large B-cell lymphoma, not otherwise specified: This lymphoid neoplasm usually arises from the lymphoproliferative disease, idiopathic multicentric Castleman disease. (
  • In cases so infected, the lymphoid neoplasm may result, at least in part, from this viral infection and therefore can be considered as examples of the Epstein-Barr virus-associated lymphoproliferative diseases. (
  • A variant of t(14;18)-negative nodal diffuse follicular lymphoma (FL) with 1p36 deletion has been proposed in the 2017 World Health Organization (WHO) classification of lymphoid neoplasms. (
  • Except for human herpesvirus 8-positive diffuse large B-cell lymphoma, not otherwise specified, these lymphoid neoplasms are often associated with Epstein-Barr virus infection of the malignant plasmablastic cells. (
  • We have especially focused on the immunophenotype of these neoplasms and have undertaken an extensive immunohistochemical analysis, using markers of epithelial, myoid, sex cord and neuroendocrine lineage as well as hormone receptors. (
  • In 3 of 4 prostate cancer patients, prostate-specific antigen (PSA) values stabilized during the course of vaccination. (
  • Objective: The ARO 96-02 trial primarily compared wait-and-see (WS, arm A) with adjuvant radiation therapy (ART, arm B) in prostate cancer patients who achieved an undetectable prostate-specific antigen (PSA) after radical prostatectomy (RP). (
  • Results: The median age of the patients was 67 years, and the median overall and prostate-specific antigen follow-up times were 6.8 years and 5.8 years, respectively. (
  • Several of the identified T-cell epitopes share similarity with common bacterial and viral antigens, suggesting the involvement of pre-existing microbial cross-reactive T cells in rapid and durable tumour regression seen in some patients. (
  • Patients with a history of a renal neoplasm presenting with acute neurological signs or symptoms should undergo which of the following imaging studies? (
  • ICD-9 code V84.09 for Genetic susceptibility to other malignant neoplasm is a medical classification as listed by WHO under the range -GENETICS (V83-V84). (
  • Each B lymphocyte recognizes a specific foreign substance, or antigen. (
  • Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. (
  • The nature and site of tumor-antigen presentation to immune T cells by bone-marrow-derived cells within the tumor microenvironment remains unresolved. (
  • The spatiotemporal dynamics revealed here implicate nonproductive interactions between T cells and antigen-presenting cells on the tumor margin. (
  • Combination of analysis of fluorescence labeling and light scatter properties of cells allows rapid and better determination of target cell antigens . (
  • Primary hepatobiliary neoplasms (PHN) are uncommon in cats, and originate in hepatocytes, intra- and extrahepatic bile ducts, mesenchymal cells, and cells of neuroendocrine origin. (
  • Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). (
  • When it encounters its specific antigen, the B cell begins to divide and multiply, producing large numbers of identical (monoclonal), mature plasma cells. (
  • These plasma cells produce large amounts of antibody that are specific for the antigen. (
  • When these IgM clusters encounter their specific antigen, usually a bacterium, they cover it so that it can be destroyed by other immune system cells. (
  • In fact, both UV-induced DNA incision and the recruitment of proliferating cell nuclear antigen (PCNA) to DNA repair sites occurred to a comparable extent in p53-wild type and -mutant cell lines, although PCNA remained associated with chromatin for a longer period of time in IGROV-1/Pt1 cells. (
  • The primary discriminator is the phenotype of the malignant cells: LP cells express CD20 and other B-cell antigens and express CD30 only rarely and weakly, while HRS cells express CD30, with downregulation of B-cell antigens such as CD20. (
  • The morphology of cancer tissue did not influence the number of specimens exhibiting STn antigen expression in mucosa adjacent to cancer cells. (
  • Murine SC142 antibody specific for the SC142-reactive antigen has been produced by immunisation with SNU16 stomach cancer cells. (
  • The four blood groups A, B, O, and AB are determined by the presence of antigens A and B or their absence (O) on a patient's red blood cells. (
  • Blood cells that express Rh(D) antigen are Rh positive. (
  • Antigen-presenting cells (APCs) are essential for stimulating antigen-specific immunity, including immunity against tumor cells. (
  • We hypothesized that systemic administration of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, which promote monocytes to differentiate into dendritic cells in vitro , might enhance the number and antigen-presenting activity of CD14 + cells in vivo . (
  • When given alone, GM-CSF increased the number of CD14 + cells but did not enhance the cells' expression of APC markers or antigen-presenting activity. (
  • The CD3 antigen is present on the cell membrane of normal T cells and is expressed in the majority of T-cell neoplasms. (
  • Antibody against CD31 strongly labels endothelial cells and neoplasms derived from endothelial cells. (
  • Factor VIII-realted antigen (vonWillebrand factor) is present in endothelial cells and in the cytoplasm of megakaryocytes. (
  • Normally, B-cells take up foreign antigens, move to the germinal centers of secondary lymphoid organs such the spleen and lymph nodes, and at these sites are stimulated by T-cell lymphocytes to differentiate (i.e. change their cell type) into plasmablasts and thereafter mature plasma cells. (
  • Among its related super-pathways are Immune System and Immune response Antigen presentation by MHC class II. (
  • Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. (
  • The unexpected frequency of human tumor antigens, which can be readily defined at the molecular level by the serological analysis of autologous tumor cDNA expression cloning, indicates that human neoplasms elicit multiple specific immune responses in the autologous host and provides diagnostic and therapeutic approaches to human cancer. (
  • The optimal prostate-specific antigen (PSA) level after radical prostatectomy (RP) for defining biochemical recurrence and initiating salvage radiation therapy (SRT) is still debatable. (
  • Detection of intracellular antigens by flow cytometry (FCM) requires effective fixation and permeabilization of the cell membrane . (
  • This antibody recognizes the antigen presenting on the cell surface membrane of tissue macrophages. (

No images available that match "antigens neoplasm"